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SUMMARY 
 human papillomaviruses (HPV) are subdivided into five species and are abundantly 
detected in the skin, in particular the  and 2 species. Therefore, HPV types are 
considered to have a cutaneous tropism. However, several recent studies have described 
the presence of  HPV also in the mucosal epithelia at different anatomical sites. In 
particular, 3 HPV types are more prevalent in certain mucosal epithelia rather than in the 
cutaneous tissues. Studies in different experimental models have also highlighted that 3 
HPV49 share functional similarities with the mucosal high-risk (HR) HPV16. However, 
with the exclusion of HPV49, very little is known about the biology of the other known 
3 HPV types (75, 76 and 115). 
The aim of this thesis was the characterization of the biological properties of E6 and E7 
of all known 3 HPV types, in relation to their interaction with key cellular pathways such 
as pRb, p53 and hTERT. 
Similar to what was previously showed for HPV49 E6/E7, HPV75 and HPV76 E6 and 
E7, but not HPV115 E6 and E7, efficiently cooperate in the immortalization/extension 
of lifespan of human foreskin keratinocytes (HFKs). In detail, HPV49, 75 and 76 E6/E7 
cause the accumulation of the phosphorylated form of pRb, leading to the release of the 
E2F factor and unscheduled S-phase entry. As observed for HR HPV16, cell cycle 
deregulation mediated by 3 HPV onco-proteins leads to p16INK4a accumulation, while no 
p16INK4a was detected in 2 HPV38 E6/E7 HFKs. Similarly to HPV49 E6, HPV75 and 
76 E6s degrade p53 via an E6AP/proteasome-mediated mechanism. Mutation in HPV76 
E6 amino-acids that correspond to HPV16 E6 amino-acids involved in the formation of 
the E6/E6AP/p53 ternary complex results in the failed immortalization of HFKs. All the 
3 HPV types, with the exception of HPV115, induce the up-regulation of hTERT 
expression, another important step in cellular transformation. Comparative analysis of 
cellular gene expression pattern of HFKs expressing E6 and E7 from HR HPV16, 3 
HPV types and β2 HPV38 further highlights the functional similarities of HR HPV16 and 
3 HPV49, 75, 76. The expression profiles of these four HPV HFKs show some 
similarities and diverge substantially from 3 HPV115 E6/E7 and 2 HPV38 E6/E7 
HFKs.  
In conclusion, the data show that 3 HPV types share some similarities with HR HPV 
types and pave the way to additional studies aiming to evaluate their tissue tropism and 
their role in human pathologies.  
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ZUSAMMENFASSUNG  
Die humanen Papillomviren (HPV) des β-Genus sind in fünf Spezies unterteilt, wobei 
insbesondere die β1- und β2-Spezies häufig in der Haut nachgewiesen werden können. 
Aus diesem Grund wird davon ausgegangen, dass die β-HPV Typen einen vorwiegend 
kutanen Tropismus haben. β3 HPV Typen werden dagegen hauptsächlich in bestimmten 
Schleimhäuten nachgewiesen und nicht wie die anderen β-Typen in kutanem Gewebe. 
Studien in verschiedenen experimentellen Modellen haben gezeigt, dass der β3 HPV Typ 
49 funktionelle Eigenschaften mit dem mukosalen Hochrisikotyp (HR) HPV16 teilt. Mit 
Ausnahme von HPV49 ist über die Biologie der restlichen, bekannten β3 HPV Typen 
(HPV75, 76 und 115) bisher nur wenig bekannt. 
Das Ziel dieser Arbeit war die Charakterisierung der biologischen Eigenschaften von E6 
und E7 aller bekannten β3 HPV-Typen im Hinblick auf ihre Interaktion mit zellulären 
Schlüssel-Signalwegen wie pRb, p53 und hTERT. Ähnlich wie HPV49 E6/E7 sind auch 
HPV75 und HPV76 E6/E7 maßgeblich an der Immortalisierung/Verlängerung der 
Lebensdauer primärer humaner Vorhautkeratinozyten (HFKs) beteiligt, ganz im 
Gegensatz zu HPV115 E6/E7. Die Expression von HPV49, 75 und 76 E6/E7 resultierte 
in der Akkumulation der phosphorylierten Form von pRB, welche zur Freisetzung des 
E2F Transkriptionsfaktors und der außerplanmäßigen S-Phase führte. Wie bereits bei HR 
HPV16 beobachtet, verursachte auch die Zellzyklusderegulation durch β3 HPV 
Onkoproteine die Akkumulation von p16INK4a, wohingegen keine p16INK4a 
Akkumulation bei β2 HPV 38 E6/E7 exprimierenden HFKs festgestellt wurde. Ebenfalls 
vergleichbar zu HPV49 E6 führte auch die Expression von HPV75 und 76 E6 zur 
E6AP/Proteasomen-vermittelten Degradation von p53. Basierend auf HPV16 E6 wurde 
der putative E6AP/p53 Interaktionsbereich im HPV76 Protein durch Mutagenese 
verändert. Alle vier untersuchten Mutanten von HPV76 E6 verloren die Fähigkeit HFK 
zu immortalisieren. Alle β3 HPV Typen, mit Ausnahme von HPV115, induzierten die 
Hochregulation der hTERT Expression, die einen weiteren wichtigen Schritt der 
zellulären Transformation darstellt. Desweiteren demonstrierten Vergleichsanalysen 
zellulärer Genexpressionsmuster von HFKs , die E6 und E7  des HR HPV16, der β3 
HPV Typen und des β2 HPV38  E6 und E7 exprimierten die Ähnlichkeit der β3 HPV 
Typen 49, 75 und 76 zum HR Typ HPV16. Das Expressionsprofil dieser vier HPV HFKs 
wies einige Gemeinsamkeiten auf und unterscheiden sich damit deutlich von den β3 
HPV115 und β2 HPV38 E6/E7 HFKs. 
Diese Daten zeigen, dass β3 HPV Typen einige Übereinstimmungen in Bezug auf ihre 
regulierenden Eigenschaften der zellulären Genexpression zu den HR HPV Typen 
aufweisen und verdeutlichen somit die Notwendigkeit weiterer Studien, zur Erforschung 
ihres Gewebetropismus und ihrer Rolle in der humanen Pathologie.   
Introduction 
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1 INTRODUCTION 
1.1 HUMAN PAPILLOMAVIRUSES 
The human papillomavirus (HPV) belong to the taxonomic family of Papillomaviridae and 
represents a group of non-enveloped double-stranded (ds) DNA viruses. The viruses that 
make up Papillomaviridae are highly diverse, and are present in most mammals and birds. 
1.1.1 PHYLOGENETIC CLASSIFICATION 
Over 240 papillomaviruses (PV) have been discovered so far, including more than 150 
HPVs, and they are grouped by species and classified into 16 genera (indicated with 
Greek letters), as shown in figure 1. This classification is based on the nucleotide 
sequence of L1, with a genotype (or type) considered distinct when the sequence is at 
least 10% divergent from other known PVs [1]. Currently, the alpha, beta and gamma (, 
, ) genera include the majority of the HPV types. 
The phylogeny classification of the PV based on the L1 nucleotide sequence does not 
necessary correlate with the biological properties of the different HPV types. As an 
example, the  genus includes HPV types with different tissue tropism and/or oncogenic 
properties. 
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Figure 1: Papillomaviruses phylogenetic tree. Classification of papillomaviruses based on L1 
gene sequences alignment. Most of the HPVs belong to the ,  (blue) and  (green) genera. the 
 genus HPV types are further sub-divided in low-risk cutaneous (light brown), low-risk 
mucosal (yellow), or high-risk mucosal (pink) according to their association with the 
development of cancer. The high-risk types highlighted with red text are confirmed as “human 
carcinogens” by IARC. Mucosal and cutaneous tropism classification is indicated under each 
genus. Figure from [2] 
Introduction 
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1.1.2 HUMAN PAPILLOMAVIRUSES GENOME ORGANIZATION 
The HPV double stranded genome is approximately 8000 base pairs in size and, despite 
the variety of HPVs, its organization is highly conserved. The genome consists of 3 
regions: (i) a non-coding long control region (LCR), (ii) an early gene region, and (iii) a 
late gene region, as shown in Figure 2. 
 
Figure 2: Schematic overview of the double-stranded DNA genome of  and  human 
papillomaviruses. In the left panel the  HPVs genome organization, in the right panel the  
HPVs genome organization. The late genes L1 and L2 are depicted in green; the early genes E1, 
E2, E4, E5, E6 and E7 are depict in blue. Notably, E5 ORF is absent in the  HPV genomes. 
The URR, also called LCR, is depict in yellow. Figure modified from [3]. 
The LCR, otherwise known as the upstream regulatory region (URR), is located between 
the late and early gene regions. It contains many of the responsive elements for 
transcription factors involved in viral gene expression as well as elements essential for 
viral DNA replication. Considerable heterogeneity exists among the LCR of the different 
PVs and, notably, the LCR of the  HPVs is shorter compared to the one of the  HPVs. 
The early gene region encodes for genes that are expressed in the early stage of the viral 
life cycle and are mainly involved in viral replication (E1, E2), cell cycle entry, and 
immune evasion (E6, E7, E5). This region also contains the E4 gene, which is expressed 
at the late stage of the viral life cycle and thought to be involved in the virus release. E4 is 
also thought to be important in the induction of the productive life cycle. 
The early protein 1 (E1), with the aid of E2, binds to the viral origin of replication and it 
assembles into a hexameric helicase. This complex exerts its function to unwind the viral 
genome, providing the template for the replication of the viral genome [4, 5]. In addition, 
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the E2 protein also acts as viral transcription regulator by interacting with various host 
proteins, modifying their function to regulate the viral life cycle. The roles of E4 and E5 
are not yet fully understood, however, E4 seems to be involved in the destabilization of 
the cytokeratin network through the formation of amyloid fibers and in the escape of the 
virions from the epithelial surface [6, 7]. E5 is a short transmembrane protein that 
mediates mitogenic signals of growth factors, such as the epidermal growth factor 
receptor or the plated derived growth factor (PDGF)  receptor [8, 9]. Remarkably, the 
E5 gene is not present in the  HPV genomes, indicating that the  HPVs have probably 
evolved to exert the same functions by different mechanisms. 
E6 and E7 are the major onco-proteins involved in the HPV-induced carcinogenesis and 
their biological properties are described in detail in paragraph 1.2. An additional gene, E8, 
is located within the E1 open reading frame (ORF) and generates a spliced transcript 
called E8^2C which has been implicated in the regulation of the viral replication [10].The 
late region comprises the L1 and L2 genes that encode the major and minor capsid 
proteins, respectively. The viral DNA is encased by a non-enveloped icosahedral capsid 
of about 50-60 nm, composed of 72 capsomers. Each capsomer is formed by five L1 and 
one L2 molecule.  
1.1.3 HUMAN PAPILLOMAVIRUS TROPISMS 
HPVs are also classified as mucosal or cutaneous types according to their ability to infect 
the mucosal epithelia or the skin, respectively. So far, well-established mucosal HPV types 
are included in genus  and they can be sub-divided into low-risk (LR) or high-risk (HR), 
accordingly to their ability to induce benign or malignant lesions respectively. The LR 
HPV types are normally associated with genital warts while HR HPV types are the 
etiological cause of cervical cancer as well as a subset of anogenital and head and neck 
cancers [11]. The classification of  HPVs in HR and LR types parallels their 
transforming abilities in in vitro (cell culture) and in vivo model (transgenic mouse). 
Many of the cutaneous HPV types belong to the  and  genera. Several findings have 
indicated that  HPV types, together with ultra-violet (UV) irradiation, promote the 
development of Non-Melanoma-Skin Cancer (NMSC) [12]. 
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It is still unclear what biological properties of the different HPV types determine their 
tissue tropism. Based on available data, one possible hypothesis is that HPV tissue 
tropism is not controlled at the entry level but it is primarily controlled by the LCR region 
that controls viral gene expression [13, 14, 15]. Since E5, E6 and E7 present more 
variability in sequence, it is possible that the tropism depends on the function and 
regulation of these genes. Another hypothesis suggests that E4, given the considerable 
heterogeneity among the sequences in the different types, may play a role in the tropism 
and in the different transmission routes [16]. 
1.2 HUMAN PAPILLOMAVIRUSES AND 
CARCINOGENESIS 
1.2.1 CANCER AND  HPV TYPES 
All HR HPV-associated cancers correspond to approximately 5% of all cancer cases 
worldwide [17]. Thirteen HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) 
are classified as carcinogenic in humans (Group 1) for their role in the development of 
cervical cancer [18]. HPV16 and HPV18 are responsible for approximately 50% and 20% 
of cervical cancer cases respectively [19, 20] 
The preferential infection site for the mucosal HPV is the junction between the 
endocervix columnar cells and the ectocervix stratified squamous epithelial cells, known 
as the cervical transformation zone. The majority of the HPV infections are cleared by the 
immune system in a relatively short time, usually between 6 and 12 months, and therefore 
do not lead to cytological abnormalities. Persistent infections that are not naturally cleared 
by the immune system are associated with the development of cervical intraepithelial 
neoplasia (CIN), which may regress or progress to invasive cervical carcinoma after a 
relatively long period of latency [21]. Figure 3 schematically shows the evolution of an 
HPV infection from CIN to invasive cancer. 
Beside HPV infection, there are various risk factors associated with the development of 
cervical cancer. These risk factors likely influence the ability of the host immune system 
to clear the virus, or they may be carcinogenic themselves. Epidemiological studies have 
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identified certain sexual habits, cigarette smoking, oral contraceptive use and host genetic 
predisposition as additional risk factors [22, 23, 24, 25, 26].  
HR HPV types are also responsible for a set of anogenital cancer (anal, vaginal, vulvar 
and penile cancers) [27] as well as oropharyngeal cancer (base of the tongue, tonsils, and 
throat) [28, 29]. However, these cancers are predominately associated with HPV16, while 
the other HR HPV types appear to play a minor role. 
Due to their association with human carcinogenesis, the mucosal HR HPV types have 
been extensively studied in the last 3 decades. Many studies have demonstrated the 
transforming properties of the viral onco-proteins in in vitro and in vivo experimental 
models. 
 
Figure 3: Stage of HPV infection, from CIN to invasive cancer. The basal layer of the 
cervical epithelium is supported by the basement membrane and by the dermis. Infectious HPV 
particles can access the basal layer, the primary site of infection, through micro abrasion. 
Following the infection, the early HPV genes are expressed in the basal layer while the late gene 
and E4 are expressed in the midzone and in superficial zone. In CIN1 and CIN2 lesions, the viral 
genome remains episomal. The progression to CIN3 is characterized by viral genome integration 
with the disruption of E2 gene and therefore up-regulation of E6 and E7. Figure modified from 
[30]. 
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HR HPV AND CELLULAR TRANSFORMATION 
HR HPV genome encodes three transforming proteins: E5, E6, and E7.The E5 onco-
protein appears to have a role in the early steps of tumour initiation [31], and its 
expression is sufficient to promote neoplasia in a transgenic mouse model [32, 33]. 
Interestingly, the E5 gene is often disrupted in cancer. This is because when the HPV 
genome integrates into the host cell, the viral genome is subjected to rearrangement. 
Almost in all the integrations, the E2-region of HPV genome is deleted or separated from 
the LCR [34, 35, 36]. As consequence, the expression of several viral genes is lost, 
including E5. The loss of E5 expression during integration provides an explanation why 
E5 is thought to be an onco-protein in the early stage of carcinogenesis when the genome 
remains mainly episomal [37]. This is likely an important step in the carcinogenic process 
as 100% of HPV18-, 80% of HPV16- and 81% of HPV31-driven cancers contain 
integrated viral genomes [38, 39] 
E6 and E7 are essential for the maintenance of the transformed phenotype and are 
actively transcribed in all HPV-positive cancer cells after integration.  
E6 AND E7 TRANSFORMATION IN EXPERIMENTAL MODELS. 
The first indication that E6 and E7 are onco-proteins and that they play an important role 
in the carcinogenesis came from the analysis of cervical cancer-derived cells such as SiHa 
and CaSki, which express both E6 and E7 [40]. The silencing of E6 and E7 in these cells 
lines resulted in the rapid cell death, proving the essential role of these proteins for the 
cell phenotype [41]. 
Multiple studies have shown that E6 and E7 display transforming abilities both in in vitro 
and in vivo experimental models. The expression of E6 and E7 of HPV16 in immortalized 
fibroblasts (NIH3T3) leads to their full transformation, with the acquisition of anchorage-
independent growth ability and ability to form tumours when injected into nude mice 
[42]. In addition, HR E6 and E7 are able to immortalize human primary keratinocytes, the 
natural host of the virus [43, 44, 45, 46, 47]. 
In accordance with the in vitro assay described above, transgenic mice expressing both 
the viral genes under the basal cell keratin 14 (K14) promoter are susceptible to the 
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development of cancer, promoted by different means such as chemical carcinogens or 
estrogen treatment [48, 49]. However, the main limitation of the transgenic mouse 
model is that viral gene expression is regulated by a host promoter and not by the 
endogenous LCR. The analysis of external factors, such as hormones, on the viral 
transcription is compromised in this model.  
A break-through in the modelling of the HPV life cycle came from the development of 
organotypic raft culture, in which the HR HPV genome can be episomally maintained in 
primary keratinocytes. In this system, keratinocytes containing HR HPV genomes are 
differentiated in vitro, leading to recapitulation of the full differentiation program of the 
host keratinocyte, and allowing for completion of the viral life cycle [50, 51, 52]. The 
main limitation of this approach is the fact that the viral genome is intact, while in 
cancer progression, the viral genome is integrated and the expression of E6 and E7 is 
therefore up-regulated. 
MAJOR STEPS INVOLVED IN CELLULAR TRANSFORMATION 
During the keratinocyte life cycle, cells exit the basal layer and migrate to the superbasal 
layer, committing to a program of terminal differentiation. [53].  
The papillomaviruses lack most of the proteins necessary for viral DNA synthesis and 
consequently, they use host DNA synthesis machinery for their own genome 
amplification, which occurs primarily during the G2-like phase [54, 55]. Therefore, it is 
vital for the HPV life cycle to uncouple differentiation, essential for the production of 
viral progeny, from the proliferation, essential for viral DNA synthesis. Thanks to the 
presence of E7, the infected cells, after they have left the basal layer, are pushed back into 
the cell cycle, which ensures that these cells maintain their proliferative potential. 
However, E7 protein is not sufficient to induce cellular immortalization. For example, 
expression of HPV16 E7 in human keratinocytes triggers an autophagy-like cell death 
[56]. This cell intrinsic tumour suppressive protection mechanism is often referred to as 
“trophic sentinel response” and is triggered when there is an oncogenic proliferative 
signal in conflict with the growth inhibitory signal generated by a lack of mitogenic 
stimulation. Usually, this results in cell death, differentiation or senescence [57]. To avoid 
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cell death by the trophic sentinel response, HPV16 E6 targets p53 for degradation via the 
proteasome pathway [58]. 
 
Figure 4: schematic outline of the major steps necessary for cellular transformation 
induced by HR HPVs. Normal keratinocytes have a limited lifespan and they exit the cell cycle 
as soon as they leave the basal layer of the epithelium. The expression of HPV16 E7 causes the 
degradation of pRb and a consequent aberrant proliferation. In normal condition, the aberrant 
proliferation causes the activation of the trophic sentinel response. The expression of HPV16 E6 
cause the degradation of p53, major responsible for the trophic sentinel response, therefore the 
cells continue to proliferate. As a last mechanism of protection from unlimited proliferation, the 
telomeres shorten at every DNA replication; the presence of E6 and E7, with still not well 
characterized mechanisms, cause the re-activation of the human telomerase, resulting in the 
immortalization of the keratinocytes.  
The expression of E6 and E7 causes extended proliferation, but this is not sufficient for 
cellular immortalization. In fact, the somatic cells have another mechanism of protection 
to limit the capacity of proliferation: the shortening of telomeres after cell division. 
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Therefore  HR HPV E6 and E7 evolved to re-activate the human telomerase (hTERT) 
in somatic cells to subvert this telomerase erosion [59, 60]. 
The major step involved in the immortalization of human primary keratinocytes are 
shown in figure 4.  
MAJOR CELLULAR TARGETS OF E7 ONCO-PROTEIN 
HPV E7 proteins are relatively small polypeptides (approximately 100 amino-acids) and 
notably, they lack any enzymatic activity. For this reason, E7 needs to hijack cellular 
protein complexes and modify their functions to promote proliferation. In human cells, 
E7 proteins are mainly located in the nucleus; interestingly the E7 protein lacks any 
recognizable nuclear targeting sequence, although it is actively transported in the nucleus 
through a non-classical Ran-dependent pathway [61, 62]. 
The main known target of E7 is the retinoblastoma tumour suppressor protein pRb (and 
the associated pocket proteins p107 and p130 [63]. pRb is a nuclear protein that regulates 
the activity of the transcription factor family E2F, which is mainly involved in the control 
of the cell cycle progression. E2F transcription factors (1-3) form a heterodimer complex 
with DP1. When the E2F1/DP1 complex is associated with pRb, it acts as a 
transcriptional repressor of genes involved not only in cell cycle progression but also 
genomic instability and apoptosis [64]. HR HPV E7 proteins can induce the degradation 
of pRb through the proteasome pathway with a mechanism that involves the 
reprogramming of the cullin 2 ubiquitin ligase complex. The destabilization of pRb results 
in the release of E2F1-DP complex, which can act as a transcriptional activator for the 
genes necessary for the entry and the progression of the S-phase [65, 66]. A schematic 
representation of the effect of the interaction betweenHPV16 E7 and pRb is shown in 
figure 5. 
As previously mentioned, PV need to uncouple the cellular differentiation program from 
proliferation. For this purpose, E7 has evolved to interact with p21CIP1, an important 
cyclin-dependent kinase (CDK) inhibitor. p21CIP1 steady-state levels increase with the 
differentiation of the cells where it inactivates cdk2 activity and therefore induces cell 
cycle arrest. In cells expressing E7 from HR  HPVs, p21 CIP1 levels are increased via 
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protein stabilization, however, cdk2 remains highly active, allowing the proliferation of 
infected cells [67, 68, 69, 70]. 
E6 of  HPVs subverts p53 functions via the proteasomal degradation. It is therefore 
interesting that E7 is also able to interfere with the p53 pathway, suggesting a redundancy 
of mechanisms for the inactivation of p53-mediated apoptosis. In normal cells, p53 half-
life is relatively short, due to degradation mediated by the ubiquitin ligase mdm2 [71]. 
However, in cells expressing E7 of HPV16, p53 is accumulated and its half-life is 
increased [72, 73]. It has also been observed that mdm2 binds p53 with a lower efficiency 
when E7 is expressed in the cells compared to normal cells. It is important to note that, 
despite the increased levels, p53 is transcriptionally inactive [74]. 
Additional functions of E7 have also been identified such as alteration of cell metabolism 
and chromosomal instability, both of which are involved in the transformation process 
[75, 76]. For other E7-interacting partners, such as histone deacetylases and histone acetyl 
transferase, their relevance for cellular immortalization is still unclear [77].  
 
Figure 5: schematic representation of HPV16 E7 effect on pRb pathway. In normal cells, 
pRb recognizes and binds E2F/DP transcription factors and repress the expression of genes 
involved cell cycle progression, genomic instability and apoptosis. HPV16 E7 binds to pRb 
causing its degradation via proteasome pathway. E2/DP complexes are released, and they 
activate the transcription of genes involved in the cell cycle progression, causing an unscheduled 
S phase.  
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E7 AND p16INK4a 
The degradation of pRb mediated by E7 is an oncogenic stress event that is sensed by the 
cells and leads to the up-regulation of the gene that encodes the CDK inhibitor p16 INK4a 
[78, 79]. 
In uninfected cells p16 INK4a inhibits the activity of CDK4 and CDK6 that phosphorylate 
pRb, therefore it causes the sequestration of E2F by the un-phosphorylated pRb and the 
cell cycle arrest [80]. 
 
Figure 6: schematic representation of HPV16 E7 effect on p16INK4a. The degradation of pRb 
is an oncogenic stress that causes an accumulation of p16 INK4a. In uninfected cells, p16 INK4a 
inhibit the phosphorylation of pRb via CDK4 and CDK6. In presence of HPV16 E7, pRb is 
degraded therefore the negative feedback is lost and p16 INK4a continues to accumulate.  
The accumulation of p16 INK4a protein, in the absence of pRb (through pRb degradation 
by HPV16 E7), causes a paradoxical increase in the levels of this protein and a surprising 
addiction to p16INK4a expression [81, 82]. In fact, p16INK4a inhibits the CDKs, however, 
the natural target pRb is degraded and p16INK4a continues to accumulate to inhibit 
uncontrolled cellular replication. A simplified representation of p16INK4a accumulation is 
shown in figure 6. 
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MAJOR CELLULAR TARGET OF E6 ONCO-PROTEIN 
HPV E6 proteins are relatively small polypeptides (approximately 150 amino-acids) and 
the main characteristic is the presence of four Cys-X-X-Cys motifs that allow the 
formation of two zinc fingers [83]. 
The major effect of the E6 onco-protein is the elimination of the trophic sentinel 
response caused by the expression of E7 through the inactivation of p53 [84]. 
It was shown several years ago that p53 is degraded via the proteasome pathway via 
hijacking of the cellular enzyme E6AP (E6 Associated Protein), as schematically 
represented in figure 7 [58, 85]. 
E6AP, also known as UBE3A, is a 100 kDa protein that acts as an E3 ubiquitin-protein 
ligase and therefore transfers ubiquitin molecules to the target protein. In an uninfected 
cell, p53 is not a natural target for E6AP, however, in HPV-infected cells, E6 diverts 
E6AP in order to induce the degradation of p53 [86, 85]. The interaction of E6 with 
E6AP causes the dimerization and ubiquitination of E6AP and subsequentially a 
conformation change that allow the binding of the E6-E6AP complex to p53 [87, 88]. 
Once p53 is ubiquitinated, it becomes available for proteasome degradation where it is a 
target for cytoplasmic proteasomes.  
The consequence of the degradation of p53 mediated by E6/E6AP is the inhibition of 
the growth arrest and apoptotic function of p53, allowing the cells to aberrantly grow 
under the stimulus of E7 expression. 
Different studies have shown that E6 can interfere with p53 function via mechanisms 
other than degradation, suggesting that there are redundant mechanisms to target the 
same pathway. HR E6 proteins can bind the histone acetyl transferase (HAT) p300, 
inhibiting its enzymatic activity. Besides its chromosomal remodeling function, p300 
acetylates p53, causing its activation as a transcription factor [89]. The interaction of E6 
with p300 causes the conversion of the p53 complexes from activators to repressors [90]. 
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Figure 7: schematic representation of HPV 16 E7 effect on p53 pathway. The interaction 
between E6 and E6AP causes a conformation change that allows the recruitment of p53 to E6-
E6AP complex. E6AP exert its function and ubiquitinates p53, targeting it for proteasome 
degradation.  
Interestingly, E6 can also interfere with the apoptosis with a mechanism that is p53-
independent. In fact, E6 binds and causes the degradation of the pro-apoptotic protein 
Bak [91]. Bak is generally sequestered and released only upon DNA damage, causing the 
release of cytochrome C and the activation of the apoptotic caspase cascade. In the 
presence of E6 Bak is degraded, therefore, its pro-apoptotic function is inhibited [92]. 
A considerable number of other interactors of E6 have been discovered, though the 
biological significance of many of these is not yet clear. Among them E6 is able to 
interact with a set of protein containing the PDZ motif; these proteins are important in 
many cellular signal transduction pathways and the interaction of E6 with these proteins 
seems to be relevant for the transforming ability of HPV [93, 94]. 
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E6 AND hTERT 
The activation of the telomerase enzyme, which adds telomere repeats to the end of 
chromosomes, is an important step in the immortalization mediated by HR  HPVs [60]. 
Different studies showed that E6 can activate the telomerase at the transcriptional level, 
causing an up-regulation of it at the mRNA level [95, 96, 97]. The mechanism by which 
hTERT is up-regulated has not been elucidated yet, however, there are suggestions that 
E6AP binding is involved [95, 96]. One model proposes that the E6-E6AP complex 
binds to the NFX1-91 (a TERT transcription repressor), leads to its ubiquitination and 
degradation and eventually it causes the E6AP-dependent de-acetylation of histones [98, 
99]. A different model indicates c-myc as a target of E6-E6AP complex binding, 
somehow causing c-myc to be a better transcriptional activator for hTERT [97]. The two 
proposed model are schematically depicted in figure 8.  
 
Figure 8: Schematic representation of the proposed model for hTERT up-regulation in 
presence of HPV16 E6. In the first model, E6-E6AP complex binds NFX1-91 and cause its 
ubiquitination and degradation. This event cause at the same time an E6AP-dependent de-
acetylation of histones. In the second model, c-myc is targeted by E6-E6AP complex leading to a 
transcriptional activation of hTERT. 
Moreover, a study [100] showed that E7 is also partially contributing to hTERT up-
regulation. In this study, they showed that in the hTERT promoter there is an E2F site 
that in normal condition act as an inhibitory element. The binding of E7 to pRb causes an 
enhancement of hTERT promoter as well as an increase in the telomerase activity. It is 
important to note that the role of E7 is marginal compared to E6 since E7 alone is 
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insufficient to initiate the transcription of the endogenous hTERT in primary 
keratinocytes. 
1.2.2 CANCER AND  HPV TYPES 
 HPVs AND EPIDERMODYSPLASIA VERRUCIFORMIS 
The first  HPV types 5 and 8 have been isolated in the skin of individuals suffering from 
a genetic disorder, known as epidermodysplasia verruciformis (EV). EV is a rare genetic 
disorder characterized by the extensive skin warts mainly located in sun-exposed areas, 
that often evolve into squamous cell carcinoma (SCC) [101, 102].  HPV 5 and 8 have 
been detected in 90% of squamous cell carcinomas found in EV affected patients, leading 
to their classification as “possibly carcinogenic” viruses [103, 104]. 
Patients with this rare disease are unable to clear  HPV infections, while they are able to 
clear  HPV infections as well as infections caused by bacteria and other viruses [105, 
106]. 
The genetic background of the disease has been identified for 75% of the cases in 
mutation in the genes that encode EVER1 or EVER2 [107]. Although the exact role of 
these two genes in the restriction of HPV infection is not completely understood, it is 
known that EVER1 and EVER2 are involved in the immune response and skin 
homeostasis [108, 109].  
 HPVs AND NON-MELANOMA SKIN CANCER 
IMMUNOSUPPRESSED INDIVIDUALS 
Immunosuppressed organ transplant recipients (OTR) are often subject to development 
of HPV-induced warts as well as actinic keratosis (AK) and cutaneous SCC [110, 111]. 
Interestingly, HPV-induced warts associate and co-localize with SCC in OTR, suggesting 
that persistent warts may progress into skin cancer [112]. Moreover, different studies have 
shown that the prevalence of  HPV DNA in the skin of OTR is higher than in the 
general population, supporting the hypothesis that  HPVs are the etiologic agent of 
NMSC in immunosuppressed individuals [113, 114]. 
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IMMUNOCOMPETENT INDIVIDUALS 
 HPV genomes are detected in NMSC but they are often also detected in the skin of 
healthy immunocompetent individuals [115, 116]. However, a meta-analysis of case 
control studies suggested that β HPV antibody positivity, in particular for the types 
5/8/17/20/38, is associated with an increased risk of development of SCC [117]. 
The prevalence of  HPV genomes is higher in the initial stage of the lesion, the actinic 
keratosis, compared to the prevalence in the SCC supporting the hypothesis of a role of 
the  HPVs in the initial stages of the carcinogenesis [118]. HPV may play a role in the 
initial stage facilitating the accumulation of UV-induced mutation (a well-established risk 
factor for skin carcinogenesis [119]) in the host genome. After the establishment of the 
cancer cell phenotype, the presence of the viral genome may not be necessary for the 
maintenance of the phenotype and therefore it could be lost. 
HUMAN PAPILLOMAVIRUS TYPE 38 
HPV38 E6 and E7 were the first onco-proteins from  types to show immortalization 
ability in human foreskin keratinocytes (HFKs) [120]. Different to the HR  HPV types, 
HPV38 E6/E7 expressing keratinocyte immortalization is preceded by a lag-phase in 
which the cells remain growth arrested [120]. 
Reflecting the different tropisms, the mechanisms, shown in Figure 9, by which E6 and 
E7 of HPV38 interact with p53 and pRb pathway are different from those used by high 
risk mucosal viruses (described in paragraph 1.2.1). HPV38 E7 induces accumulation of a 
specific form of p53, that is phosphorylated at serine residues 15 and 392 [121]. This 
particular form of p53 is efficiently recruited to an internal promoter of p73 causing the 
expression of the truncated form Np73, which acts as an antagonist of the p53-
regulated pathway [121]. In addition, HPV38 E6 binds p53 with high affinity, however, 
the consequence of this interaction remains to be fully characterized [122]. 
Similar to HR  types, HPV38 E7 can associate with pRb, however, its expression in 
human primary keratinocytes leads to a stabilization of pRb in the hyperphosphorylated 
form [120]. In this form, pRb loses the ability to bind E2F transcription factors and 
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therefore E2Fs can induce the expression of the genes involved in the G1/S transition 
[64]. 
 
Figure 9: Schematic representation of HPV38 E6/E7 effects on p53 and pRb pathways. 
HPV38 E7 induces an accumulation of p53 phosphorylated at serines 15 and 392 and 
consequently a nuclear accumulation of Np73, that act as an antagonist of the p53-regulated 
pathway. The consequence of the interaction between HPV38 E6 and p53 remains to be fully 
characterized. HPV38 E6 bind MAML1 and that causes the repression of Notch transcriptional 
activation. An additional interaction partner of E6 is E6AP, that target NFX1-91 for degradation, 
causing the transcriptional activation of hTERT. Finally, HPV38 E7 leads to the stabilization of 
pRb in the hyperphosphorylated form. 
As discussed for HPV16 in paragraph 1.2.1, HPV38 E6 and E7 have additional 
interaction partners. It is important to note that, similar to all the  HPVs, E6 binds 
MAML1 (Mastermind-like 1) and in doing so causes the repression of Notch 
transcriptional activation [123, 124, 125]. The Notch signaling pathway plays an important 
role in cell-cycle exit and keratinocyte differentiation [126, 127]. Therefore, it is possible 
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that this interaction would benefit the viral life cycle since HPV needs to uncouple 
differentiation and proliferation to complete its life cycle. 
Moreover, HPV38 can up-regulate the expression of hTERT with two distinct 
mechanisms. E6 is able to activate the transcription via E6AP and NFX1-91 binding 
[128] while E7 promotes the accumulation of Np73 which in turn positively regulates 
hTERT [129]. 
Transgenic (Tg) mouse models expressing E6 and E7 of HPV38 in the basal layer of the 
epidermis under the control of the K14 promoter (cytokeratin promoter) have a higher 
susceptibility to skin cancer compared to wild-type animals only when exposed to UV-
radiations [130]. When exposed to UV-irradiation for few weeks, the mice first develop 
lesions similar to the human AK and later they develop SCC [130]. Interestingly, the Cre-
LoxP mediated deletion of E6 and E7 after the development of UV-induced skin lesions 
did not affect tumour growth [131]. This recent data support the hypothesis that  
cutaneous types have a “hit and run” mechanism, accentuating the deleterious effects of 
the UV radiation. 
1.2.3 CANCER AND  TYPES 
In addition to their ability to target the skin, recent findings have indicated that  HPV 
types can also infect other anatomical sites such as the oral mucosal epithelium, eyebrow 
hairs, penile and external genital lesions [132, 133, 134, 135]. Although no findings have 
supported the direct involvement of HPV types in pathological conditions at any of the 
anatomical sites described above, a prospective study showed that DNA positivity for 
some  HPV types in the oral cavity was associated with the risk of head neck and cancer 
[136]. 
Of particular interest are the types (HPV49, 75, 76 and 115), that are often found more 
frequently in mucosal epithelia rather than in the skin [137, 135]. 
Interestingly biological studies on HPV49 have shown that E6 and E7 of this  type 
share some functional similarities with HR HPV16 onco-proteins [138]. 
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HUMAN PAPILLOMAVIRUS TYPE 49 
Like HPV16 and HPV38, expression of HPV49 E6 and E7 leads to the immortalization 
of human primary keratinocytes. Interestingly, the expression of E6/E7 from HPV49 
determines the continuous growth of the cells without the lagging phase that characterizes 
the other  types, such as HPV38 [138]. 
Another interesting similarity with HPV16 is the ability of HPV49 E6 to bind the 
ubiquitin E3 ligase enzyme, E6AP, and to promote p53 degradation via the proteasome 
pathway [138]. The mechanism of interaction with p53 is clearly different from the one 
described for other  HPV types, such as HPV38 [120, 121]. 
By contrast, the mechanism of interaction with pRb pathway is similar to what has been 
observed for HPV38 with the accumulation of the phosphorylated form of pRb and the 
subsequent release of E2F [138]. 
Other additional interaction partners have been identified also for HPV49 E6 and E7; 
among these MAML1 interacts with E6, similar to what has been shown for many other 
 HPVs [122]. It is interesting to note that E6 of HPV49 is the only E6 protein of  types 
proven to be able to interact with both E6AP and MAML1 [122], supporting the 
hypothesis of intermediate characteristics of this papillomavirus.  
Transgenic mouse models, expressing E6 and E7 under the control of K 14 promoter, 
provide further evidence for the functional similarities between HPV types 16 and 49. 
K14  HPV type 49 or  HPV type 16 E6/E7-Tg animals were found to be highly 
susceptible to upper digestive tract carcinogenesis upon initiation with 4-nitroquinoline 1-
oxide (4NQO), while K14 2 HPV type 38 E6/E7-Tg mice were not affected much by 
4NQO treatment [139].  
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2 AIM OF THE THESIS 
Although more than 200 human papillomavirus types have been isolated so far, only a 
small number of these have been extensively studied with respect to their biological 
properties and association with human diseases. Within the beta genus, species 3 types 
(HPV49, 75, 76 and 115) are of particular interest for their dual tropism for cutaneous 
and mucosal epithelia, and for the similarities that E6 and E7 of HPV49 share with the 
high risk  type 16 [137, 135, 138]. The epidemiological and molecular findings indicate 
that the 3 species may represent a subgroup of beta types with shared properties with  
HR HPV types. 
However, with the exclusion of HPV49, very little is known about the biology of the 
remaining known 3 HPV types (75, 76 and 115).  
Therefore, this thesis aimed to compare the immortalization properties of E6 and E7 of 
all four 3 HPV types and their ability to interfere with major events related to cellular 
transformation, such as those controlled by pRb and p53. 
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3 MATERIALS 
3.1 BIOLOGICAL MATERIAL 
3.1.1 PROCARYOTIC CELLS 
SUBCLONING EFFICIENCY™ DH5™ COMPETENT CELLS 
(INVITROGEN) 
Subcloning Efficiency™ DH5™ Competent Cells are an E.coli strain used for the 
cloning of the gene of interest into plasmid vectors. This strain has been designed to have 
high transformation efficiency: >1*106 transformed bacteria/µg DNA. 
The cells grow at 37 °C. 
RESISTANCE: None. 
GENOTYPE: F- ɸ80lacZ∆M15 ∆(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-,mk-) 
phoA supE44 thi-1 gyrA96 relA1λ  
ROSETTA  
The Rosetta™ host strain derives from the BL21 strain and it’s designed to enhance the 
expression of eukaryotic proteins. For this purpose, this strain is engineered to supply 
tRNAs that are common in the eukaryotic codon usage but rare in E. coli. The Rosetta 
strain carries the pRARE plasmid (with the chloramphenicol resistance gene), suppling 
tRNAs for the codons AUA, AGG, AGA, CUA, CCC, and GGA. Moreover, this strain 
carries a chromosomal copy of the T7 RNA polymerase under the control of the lacUV5 
promoter. Therefore, the Rosetta strain can be used to produce recombinant protein 
from genes cloned in pET system, after the induction with IPTG. 
RESISTANCE: Chloramphenicol. 
GENOTYPE: F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE (CamR) 
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3.1.2 EUKARYOTIC CELLS 
NIH/3T3 
NIH 3T3 mouse embryonic fibroblast cells come from a cell line isolated and initiated at 
the New York University School of Medicine, Department of Pathology. The line has 
been obtained from desegregated NIH Swiss mouse embryo fibroblasts and now is 
recognized as the standard fibroblast cell line.  
MEDIUM: DMEM +++ 
PHOENIX 
The Phoenix cell line has been developed by the Nolan lab in Stanford University from 
the 293T cell line (a human embryonic kidney line transformed with adenovirus E1a and 
carrying a temperature sensitive T antigen co-selected with neomycin). The Phoenix cells 
can be used as a packaging line since they carry a construct capable of producing gag, pol 
and env for ecotropic and amphotropic viruses. The unique feature of this cell line is that 
it is highly transfectable with either calcium phosphate mediated transfection or lipid-
based transfection protocols-- up to 50% or higher of cells can be transiently transfected.  
MEDIUM: DMEM +++ 
PRIMARY KERATINOCYTES 
Human primary keratinocytes cells are found in the basal layer of the stratified epithelium 
and they have different roles. The structural role is to form tight junctions with the nerves 
of the skin and keep Langerhans cells and lymphocytes of the dermis, in place. Since the 
skin is the first line of defence, keratinocytes play also a role in immune system. The 
keratinocytes, in fact, serve as a barrier between the organism and its environment. They 
prevent the entering of pathogens and toxin into the body, but they also prevent the loss 
of moisture and heat. These cells are also immune-modulators: they secrete inhibitory 
cytokines in the absence of injury meanwhile they stimulate inflammation in response to 
injury. 
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The HPK used for this project were isolated from the foreskin of 3 different donors and 
donate to the group by the following groups:  
- Donor 1: cells donated by Dr. Hans-Jürgen Stark - Genetics of Skin 
Carcinogenesis (DKFZ, Heidelberg) 
- Donor 2 and 3: cells donated by the Laboratoire des substituts cutanes, Hopital E. 
Herriot (Lyon, France).  
MEDIUM: FAD 
NATURALLY IMMORTALIZED KERATINOCYTES (NIKS) 
The NIKs cell line was isolated and characterized by Allen-Hoffmann et al. in 2000. This cell 
lined arose from the BC-1-Ep strain of normal foreskin keratinocytes and maintained 
steady-state levels of transforming growth factor (TGF-), transforming growth factor-
1, epidermal growth factor receptor, c-myc, and keratin 14 mRNAs, similarly to the 
parental cell line. NIKs are non-tumourigenic and produces a fully stratified squamous 
epithelium in organotypic culture [140]. 
MEDIUM: DMEM +++ 
HNC136 
HNC136 cell line is derived from head and neck tumour patient.  
MEDIUM: DMEM +++ 
  
Materials 
  
27 
 
3.2 MEDIA AND SUPPLEMENTS 
3.2.1 PROCARYOTIC CELLS 
LB MEDIUM 
 Concentration 
Tryptone 1% (w/v)  
Yeast Extract 0.5% (w/v)  
NaCl 0.5% (w/v)  
Deionized H2O To volume 
Adjust the pH to 7,5. Autoclave it. 
 
LB AGAR MEDIUM 
 Concentration 
Tryptone 1% (w/v)  
Yeast Extract 0.5% (w/v)  
NaCl 0.5% (w/v)  
Agar 1.5% (w/v)  
Deionized H2O To volume 
Autoclave it. Add antibiotics when the temperature is lower than 40 °⁰ C. 
ANTIBIOTICS 
 Working concentration 
Ampicillin (Amp) 100 µg/ml 
Kanamycin (Kan) 50 µg/ml 
Chloramphenicol (Chl) 25 µg/ml 
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3.2.2 EUKARYOTIC CELLS 
FAD 
 Working 
concentration 
Company 
Ham’s F-12, with L-Glutamine 73 % (v/v) GIBCO, Invitrogen 
DMEM high glucose with glutamine 
(= Dulbecco’s Modified Eagle 
Medium) 
23% (v/v) GIBCO, Invitrogen 
Fetal Bovine Serum (FBS) 4 % (v/v) GIBCO, Invitrogen 
Pen Strep (Penicillin/Streptomycin) 100 U/ml GIBCO, Invitrogen 
Adenine, (6-aminopurine) 24 µg/ml SIGMA 
Recombinant Human EGF 
(= Epidermal Growth Factor) 
10 ng/ml R&D company 
Insulin solution human 10 µg/ml Sigma Aldrich 
Hydrocortisone 400 ng/ml Sigma Aldrich 
Ciprofloxacin hydrochloride 10 µg/ml EUROMEDEX 
Cholera Toxin 8,3 ng/ml List Biological laboratories, INC 
 
DMEM + + + 
 Working 
concentration 
Company 
DMEM high glucose with glutamine 90% (v/v) GIBCO, Invitrogen 
Fetal Bovine Serum (FBS) 10 % (v/v) GIBCO, Invitrogen 
Pen Strep (Penicillin/Streptomycin) 100 U/ml GIBCO, Invitrogen 
Ciprofloxacin hydrochloride 10 µg/ml EUROMEDEX 
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OPTI-MEM 
Opti-MEM™ Reduced Serum Medium, GIBCO, Invitrogen 
DPBS 
“Dulbecco's phosphate-buffered saline” by Gibco. 
TRYPSIN 
Trypsin-EDTA (0,25%), phenol red, Life Technologies 
MITOMYCIN C 
Mitomycin C from Streptomyces caes 2mg, Sigma Aldrich  
CRYOMEDIUM 
90% FBS + 10% DMSO 
3.3 HUMAN CELLS TREATMENTS AND 
MANIPULATION 
Designation Company 
MG132 Sigma Aldrich #C2211 
Cycloheximide Ozyme #2112S 
Doxorubicin Sigma Aldrich #D1515 
Lipofectamine 2000 Invitrogen #11668027 
PolyFect Qiagen #301105 
Effectene Qiagen #301425 
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3.4 RETROVIRAL INFECTION 
Designation Company 
CalPhos Mammalian transfection kit  BD-Biosciences 
Chloroquine 25 mM Sigma Aldrich 
Polybrene 5mg/ml Sigma Aldrich 
G418 100 mg/ml Sigma Aldrich 
3.5 MOLECULAR CLONING 
3.5.1 PLASMIDS 
pLXSN 
pLXSN is a retroviral vector composed of elements from Moloney murine leukemia virus 
(MoMuLV) and Moloney murine sarcoma virus (MoMuSV). The 5’ LTR comprises 
promoter/enhancer sequences that control the transcription of + extended viral 
packaging signal and of the gene of interest, which is cloned into the multiple cloning site 
(MCS). The MCS has four unique cloning sites that are EcoRI, HpaI, XhoI, and BamHI. 
The SV40 early promoter PSV40e regulates transcription of the neomycin resistance gene 
for eukaryotic selection. The ColE1 origin of replication serves for replication of pLXSN 
in bacteria as well as the ampicillin resistance gene allows selection of pLXSN-
transformed bacteria. After transfection of pLXSN into a packaging cell line, pLXSN 
expresses the + packaging signal generating infectious but replication-incompetent 
retroviral particles. The pLXSN features are shown in the schematic representation of 
figure 10. 
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Figure 10: pLXSN vector features. pLXSN is a 5874 bp retro-viral vector containing the 
MoMuLV 5’ LTR that control the transcription of Psi packaging signal and of the gene of 
interest. The neomycin resistance (in red), allow the selection of successfully infected cells. The 
ampicillin resistance gene (in orange) with its promoter allows for selection in bacteria. 
Description Reference 
pLXSN(E6/E7)HPV16 M. Tommasino 
pLXSN(E6/E7)HPV49 M. Tommasino 
pLXSN(E6/E7)HPV75 This thesis 
pLXSN(E6/E7)HPV76 This thesis 
pLXSN(E6/E7)HPV115 This thesis 
pLXSN(E6/E7)HPV76 mut E39R This thesis 
pLXSN(E6/E7)HPV76 mut Y42R This thesis 
pLXSN(E6/E7)HPV76 mut D44A This thesis 
pLXSN(E6/E7)HPV76 mut F45E This thesis 
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pET MBP 1C  
The pET system is used for the expression of recombinant proteins in E. coli, under the 
control of a strong bacteriophage T7 transcription. The expression of the recombinant 
protein can be induced only when the system is provided with a source of T7 DNA 
polymerase, usually using engineered E. coli strain (such as the Rosetta strain). The use of 
the T7 induction system ensures the target gene expression is silent in the un-induced 
state as well as the high quantity of the protein of interest after the induction. Target 
genes are firstly cloned using non-expressing hosts (such as DH5 strain) and afterword 
transferred to expression host, where the T7 DNA polymerase gene is under the control 
of the lac promoter and therefore can be induced by the addition of IPTG. 
The pET-MBP_1c plasmid is a pET vector modified by Gunter Stier (Universität 
Heidelberg, Heidelberg, Center for Biochemistry) to carry the ORF of the Maltose 
Binding Protein (MBP). This modified version of the pET vector maintains all the 
characteristics of the pET system and, in addition, the recombinant protein is expressed 
as a fusion protein with the maltose binding protein. The MBP is a part of the 
maltose/maltodextrin system of Escherichia coli and can be used to increase the solubility 
of recombinant proteins. The mechanism underlying the increased solubility of the fusion 
proteins is still not fully understood but the MBP is able to prevent the aggregation of the 
protein of interest. Moreover, the MBP can be used as an affinity tag for the purification 
of the recombinant proteins using amylose coupled-beads. 
The pET MBP 1c features are shown in the schematic representation of figure 11. 
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Figure 11: pET MBP 1c vector features. The main feature of this plasmid is the maltose 
binding protein gene (in pink). This gene can be expressed only in presence of T7 DNA 
polymerase that recognizes the T7 binding site. The kanamycin resistance gene (in orange) allows 
the selection of successfully transformed bacteria.  
Description Reference 
pET MBP 1c (E6) HPV16 This thesis 
pET MBP 1c (E6) HPV49 This thesis 
pET MBP 1c (E6) HPV75 This thesis 
pET MBP 1c (E6) HPV76 This thesis 
pET MBP 1c (E6) HPV115 This thesis 
pET MBP 1c (E6) HPV76 mut E39R This thesis 
pET MBP 1c (E6) HPV76 mut Y42R This thesis 
pET MBP 1c (E6) HPV76 mut D44A This thesis 
pET MBP 1c (E6) HPV76 mut F45E This thesis 
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3.5.2 ENZYMES 
Designation Company 
Restriction enzymes New England Biolabs 
HotStarTaq DNA Polymerase Qiagen 
T4 DNA ligase Roche 
Mesa Green qPCR Master Mix Plus for SYBR Assay (Eurogentec) Eurogentec 
3.5.3 OLIGONUCLEOTIDES FOR siRNA KNOCKDOWN 
Designation Sequence Company 
ON-TARGETplus Human UBE3A siRNA 
(E6AP) 
Not provided 
Dharmacon 
(L005137000005) 
ON-TARGETplus Human CDKN2A siRNA 
(p16) 
Not provided 
Dharmacon 
(L-011007-00-0005) 
Scramble Not provided Eurofins 
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3.5.4 OLIGONUCLEOTIDES FOR CLONING 
All the listed nucleotides have been designed to have four adenines (AAAA) at the 5’, in 
order to improve the cutting of the PCR product by the restriction enzymes. 
All oligonucleotides listed were ordered and produced at MWG Eurofins in Ebersberg, 
Germany. 
n= nucleotide introduced to restore the frame in the fusion protein 
Highlighted in blue EcoRI restriction site 
Highlighted in red BamHI restriction site 
Highlighted in green NcoI restriction site 
 
 
 
Vector # Gene 
Restriction 
enzyme 
Sequence 5’-3’ 
p
L
X
S
N
 1 (E6)HPV76 fw EcoRI AAAAGAATTCATGGCTAGACCTGCTAAGGT 
2 (E7)HPV76 rev BamHI AAAAGGATCCTTATCGTCCGCCATTGCGAAT 
p
E
T
 M
B
P
 1
c
 
3 (E6)HPV16 fw NcoI AAAACCATGGgtATGCACCAAAAGAGAACTGCA  
4 (E6)HPV49 fw NcoI AAAACCATGGgtATGGCTAGACCTGTTAAGGTA 
5 (E6)HPV75/6 fw NcoI AAAACCATGGgtATGGCTAGACCTGCTAAGGTA  
6 (E6)HPV115 fw NcoI AAAACCATGGgtATGGCTAGGCCAGGCAGGG 
16 (E6)HPV16 rev BamHI AAAAGGATCCTTACAGCTGGGTTTCTCTACG 
17 (E6)HPV49 rev BamHI AAAAGGATCCTCATTCTATAACTCTGCAATG  
18 (E6)HPV75 rev BamHI AAAAGGATCCTCATTCTATCACTCTGCAATG  
19 (E6)HPV76 rev BamHI AAAAGGATCCTCATTCTATTACTCTGCAATG 
20 (E6)HPV115 rev BamHI AAAAGGATCCTCATTCTATTGTTCTACAATG  
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3.5.5 OLIGONUCLEOTIDES FOR REAL TIME PCR (RT-PCR) 
All oligonucleotides listed were ordered and produced at MWG Eurofins in Ebersberg, 
Germany. 
Gene Sequence 5’-3’ 
Cdc2 
fw: AATCTATGATCCAGCCAAACGAA  
rev: TTCTTAATCTGATTGTCCAAATCATTAAA 
Cdk2 
fw: GGCTGCATCTTTGCTGAAAT 
rev: CCCAGAGTCCGAAAGATCCG 
p21 
fw: GACACCACTGGAGGGTGACT 
rev: CCACATGGTCTTCCTCTGCT 
PUMA 
fw: GGATGAAATTTGGCATGGGGTCT 
rev: GGACAAGTCAGGACTTGCAG 
hTERT 
fw: TTC AAG GCT GGG AGG AAC AT 
rev: ACA TGC GTG AAA CCT GTA CG 
SERPINE 
fw: ATCGAGGTGAACGAGAGTGG 
rev:ACTGTTCCTGTGGGGTTGTG 
MT1X 
fw: AACTCCTGCTTCTCCTTGCC 
rev: GCTCTATTTACATCTGAGAGCACAG 
GADD45a 
fw: TGCGAGAACGACATCAACAT 
rev: GCAGGATCCTTCCATTGAGA 
GAPDH 
fw: AAGGTGGTGAAGCAGGCGT 
rev: GAGGAGTGGGTGTCGCTGTT 
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3.5.6 OLIGONUCLEOTIDES FOR SITE-DIRECTED MUTAGENESIS 
All oligonucleotides listed were ordered and produced at MWG Eurofins in Ebersberg, 
Germany. 
HPV76 
mutant  
Sequence 5’-3’ 
Mutagenized 
codon 
E39R 
fw: CTGACCTATTGGGAACTCTTACGGTTTGATTATAAGGA 
CTTCC 
GAG  CGG 
rev: GAAGTCCTTATAATCAAACCGTAAGAGTTCCCAATAG 
GTCAG 
Y42R 
fw: GGGAACTCTTAGAGTTTGATCGGAAGGACTTCCATTT 
AGTGTGG 
TAT  CGG 
rev: CCACACTAAATGGAAGTCCTTCCGATCAAACTCTAAGA 
GTTCCC 
D44A 
fw: CTTAGAGTTTGATTATAAGGCCTTCCATTTAGTGTGGA 
AGGACG 
GAC  GCC 
rev: CGTCCTTCCACACTAAATGGAAGGCCTTATAATCAAAC 
TCTAAG 
F45E 
fw: CTTAGAGTTTGATTATAAGGACGAGCATTTAGTGTGG 
AAGGACGG 
TTC  GAG 
rev: CCGTCCTTCCACACTAAATGCTCGTCCTTATAATCAAA 
CTCTAAG 
Highlighted in red the mutagenized codon 
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3.5.7 BUFFERS AND SOLUTIONS 
AGAROSE GEL ELECTROPHORESIS 
Designation Composition / Company 
50X TAE buffer ABCYS Eurobio 
Massruler Loading Dye Life Technologies 
MassRuler DNA Ladder, Mix, ready-to-use Life Technologies 
GelRed staining Biotium 
1% agarose gel 
1% agarose (w/v) 
1X TAE buffer 
0.004 % GelRed (v/v) 
3.6 REAGENTS FOR PROTEIN ANALYSIS 
3.6.1 ENZYMES 
Lambda Protein Phosphatase, New England Biolabs. 
3.6.2 IP BUFFER 
Ingredient Working concentration 
Tris HCl pH 7.5 20 mM 
NaCl 200 mM 
EDTA 1 mM 
NP40 0.5% 
H2O Up to 10 ml 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail 
(Roche) 
1 tablet 
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3.6.3 PROTEIN BUFFER 10X 
Ingredient  
Glycin 144.1g 
TRIS 30.3 g 
H2O To volume of 1 l 
3.6.4 SDS-POLYACRYLAMIDE ELECTROPHORESIS 
The following recipes are intended for one gel (1.5 mm) using the “Mini-PROTEAN” 
cast system from Biorad.  
RUNNING GEL 
Ingredient 
Volume 
Gel 10% Gel 12% 
Acrylamide 30% 3.3 ml 4.0 ml 
Tris 1 M pH 8.8  2.5 ml 2.5 ml 
SDS 10%  0.1 ml 0.1 ml 
APS 10% 0.1 ml 0.1 ml 
TEMED 0.004 ml 0.004 ml 
H2O 4.0 ml 3.3 ml 
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STACKING GEL 
Ingredient Volume 
Acrylamide 30% 0,33 ml 
Tris 0,5 M pH 6.8  0,25 ml 
SDS 10%  0,02 ml 
APS 10% 0,02 ml 
TEMED 0,002 ml 
H2O 1,4 ml 
RUNNING BUFFER 
Ingredient Volume 
Protein buffer 10x 100 ml 
SDS 10 ml 
H2O 890 ml 
PROTEIN MARKER 
PageRuler™ Prestained Protein Ladder, 10 to 180 kDa; Thermo Fisher (Germany) 
LAEMMLI BUFFER 6X 
Ingredient  
SDS 1.2 g 
Bromophenol blue 6 mg 
Glycerol 4.7 ml 
Tris HCl 0.5 M pH 6.8 1.2 ml 
Beta-mercaptoethanol 0.5 ml 
H2O 2.1 ml 
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3.6.5 WESTERN BLOT ANALYSIS 
TRANSFER BUFFER 
Ingredient Volume 
Protein buffer 10x 100 ml 
Methanol 200 ml 
H2O 700 ml 
OTHER SOLUTIONS 
Designation Composition/Company 
Blocking solution 10 % (w/v) skim milk  
PBS Tween 
Antibody buffer 5 % (w/v) skim milk 
PBS Tween 
PBS Tween 1X PBS 
0.064 % (v/v) 
Stripping solution 15 g Glycine 
10 ml Tween 20 
1 g SDS 
1 l H2O, pH 2.2 
Clarity™ Western ECL Blotting Substrates BioRad, Munich, Germany 
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3.7 IMMUNOLOGICAL ASSAYS 
3.7.1 ANTIBODIES 
All the following antibodies have been used with a 1:1000 dilution if not differently 
stated. 
Designation Description Reference 
β-actin (C4) Mouse monoclonal antibody detecting human actin. 
MP Biomedicals, 
 #0869100 
Phospho pRb 
(Ser795) 
Polyclonal rabbit antibody that detects endogenous levels 
of Rb only when phosphorylated at serine 795. 
Cell signaling, 
 #9301 
Total pRb 
Mouse monoclonal antibody that recognizes an epitope 
between amino acids 332-344 of the human 
retinoblastoma protein. 
BD Pharma, 
 #554136 
Cdc2 (ab-2) Mouse monoclonal antibody detecting Cdc2/Cdk1 
Calbiochem, 
 #CC01 
Cyclin A (H-432) 
Rabbit polyclonal antibody raised against full length cyclin 
A of human origin. 
Santa Cruz, 
#sc751 
p16INK4a Mouse monoclonal to CDKN2A/p16INK4a 
NovoCastra, 
DCS-50  
p53 DO1 
Mouse monoclonal antibody raised against amino acids 
11-25 of p53 of human origin. 
Santa Cruz, 
 #sc126 
E6AP-330 
Mouse monoclonal Anti-E6AP antibody purified from 
hybridoma cell culture. 
Sigma Aldrich, 
 #E8655 
GAPDH (6C5) Mouse monoclonal antibody raised against GAPDH. 
Santa Cruz, 
 #sc-32233 
Secondary mouse (dil 
1:2000) 
Anti-Mouse IgG (H+L), HRP Conjugate 
Promega, 
W4021 
Secondary Rabbit (dil 
1:2000) 
Anti-Rabbit IgG (H+L), HRP Conjugate 
Promega, 
W4011 
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3.8 MALTOSE BINDING PROTEIN PULLDOWN 
BUFFER AND SOLUTIONS 
Designation Composition  
IPTG 100 mM 
0,238 g IPTG 
10 ml H2O 
IP buffer See 6.6.2 
MBP-buffer 
10 mM Hepes pH 7.4 
100 mM NaCl 
1 mM EDTA 
10% Glycerol 
0,1% triton X-100 
BEADS 
Anti-MBP Magnetic Beads. E8037S, New England Biolabs. 
3.9 ILLUMINA ARRAY 
3.9.1 INSTRUMENTS AND CONSUMABLE 
Designation Company 
Nanodrop® Thermo Scientific 
2100 bioanalyzer  Agilent 
RNA 6000 Nano kit Agilent 
HumanHT-12 v4 Expression BeadChips  Illumina 
TotalPrep RNA Amplification Kit (Ambion®) Illumina 
BeadArray Reader Illumina  
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3.9.2 SOFTWARE 
Designation Company 
Genome Studio V2010.2  Illumina  
BRB-ArrayTools software v4.2 https://brb.nci.nih.gov/BRB-ArrayTools/  
R software https://www.r-project.org/  
Venny http://bioinfogp.cnb.csic.es/tools/venny/ 
3.10 LIQUID CHROMATOGRAPHY AND MASS 
SPECTROMETRY 
3.10.1 INSTRUMENTS AND CONSUMABLES 
Designation Company 
0.2 m Captiva ND plates Agilent Technologies 
a Rapid EPS well plate sealing tape BioChromato 
6550 quadrupole time-of-flight mass spectrometer coupled to 
1290 Infinity UHPLC system 
Agilent Technologies 
Acquity UPLC HSS T3 column (1.8 m, 2.1 × 100 mm) Waters 
3.10.2 SOFTWARE 
Designation Company 
MassHunter Acquisition B.05.01 Agilent Technologies 
MassHunter Qualitative Analysis B.06.00 Agilent Technologies 
DA Reprocessor, Mass Profiler Professional 12.1 Agilent Technologies 
Profinder B 06.00 software Agilent Technologies 
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3.11 CHEMICALS 
All chemicals were of analytical grade or better and purchased from one of the following 
companies: 
Company Location 
Gibco  Eggenstein, Germany 
Life Technologies Karlsruhe, Germany 
Fisher-Scientific Schwerte, Germany 
Merck Darmstadt, Germany 
Roth Karlsruhe, Germany 
Sigma-Aldrich Munich, Germany 
3.12 KITS 
Designation Company 
QIAquick PCR Purification Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QuikChange Lightning Site-Directed Mutagenesis Kit Agilent technologies 
NucleoSpin® RNA extraction kit MACHEREY-NAGEL GmbH 
RevertAid First Strand cDNA Synthesis Kit Thermo Fisher 
NucleoSpin® Plasmid mini prep kit MACHEREY-NAGEL GmbH 
PureLink™ HiPure Plasmid Filter Maxiprep Kit Invitrogen 
Senescence -Galactosidase Staining Kit Cell Signalling 
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3.13 LABORATORY EQUIPMENT 
3.13.1 ELECTRICAL EQUIPMENT 
Designation Company 
800 W microwave Bosch, Gerlingen-Schillerhohe, Germany 
Bacterial culture shaker Informs AG, Bottmingen, Switzerland 
Microbio Safe 12 hood Thermo Fisher, Germany 
Incubateur CO2 jaquette eau series 3 Thermo Fisher, Germany 
Developing Machine AgfaCurix60 Agfa, Munich, Germany 
Computers and monitors Dell, Round Rock, United States 
ChemiDoc™ XRS+ System BioRad, Munich, Germany 
Mini-PROTEAN® Tetra Handcast 
Systems 
BioRad, Munich, Germany 
Sub-Cell® GT Cell BioRad, Munich, Germany 
Mini Trans-Blot® Cell BioRad, Munich, Germany 
PowerPac™ Basic Power Supply BioRad, Munich, Germany 
GFC water bath Grant Instruments, Cambridge, UK 
Ice maker Hoshizaki, Willich-Munchheide, Germany 
Impulse Sealer RNS Corp, Taipei, Taiwan 
Integra pipetboy 
Integra Bioscience GmbH, Fernwald, 
Germany 
Cell counter Biorad TC20 ™ 
microscope Statif inverse TS100  NIKON 
MilliQ ultra-pure water unit  Millipore Merck, Darmstadt, Germany  
Nanodrop spectrophotometer  PegLab, Erlangen, Germany  
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Designation Company 
Nitrogen tank Chrono  Messer, Krefeld, Germany  
pH meter  Sartorius, Göttingen, Germany  
Refrigerators and freezers  Liebherr, Ochsenhausen, Germany  
Sartorius Scale  Sartorius, Göttingen, Germany  
Thermomixer 5436  Eppendorf, Hamburg, Germany  
Ultra-low freezer  Eppendorf Inc., Enfield, USA  
Vortex Genie 2™  Bender and Hobein, Ismaning, Germany  
Western Blot Exposition Cassette  Kodak, Stuttgart, Germany  
Centrifuge 5810  Eppendorf, Germany 
Centrifuge 5430  Eppendorf, Germany 
Centrifuge 5424R (cold) Eppendorf, Germany 
Centrifuge 5415D  Eppendorf, Germany 
Centrifuge 5417C  Eppendorf, Germany 
Centrifuge 5415R  Eppendorf, Germany 
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3.13.2 COMMON USE EQUIPMENT 
Designation Company 
1,5 ml and 2 ml reaction tubes Eppendorf, Hamburg, Germany 
0,2 ml reaction tubes Eppendorf, Hamburg, Germany 
15 ml reaction tubes Fisher Scientific, Waltham, United States 
50 ml reaction tubes Fisher Scientific, Waltham, United States 
25 cm2, 75 cm2 and 150 cm2 tissue culture 
flasks 
Fisher Scientific, Waltham, United States 
6, 10 and 15 cm cell culture plates Corning, New York, United States 
6-, 12-, 24-, 48 and 96-well tissue culture 
plates 
Corning, New York, United States 
Cryotubes, 2 ml Carl Roth GmbH, Karlsruhe, Germany 
Examination gloves XCEEDTM Nitril Starlab, Ahrensburg, Germany 
One-time use filter, 0.2/0.4 m Renner, Dannstadt, Germany 
Parafilm “M”  American National Can, Chicago, USA 
qPCR 96 well plate non skirted white Eurogentec, France 
Petri dishes Greiner, Frickenhausen, Germany 
Pipettes (1000, 200, 20, 10 and 2l) Gilson Middleton, USA  
Pipette Tipps (1000, 200l, 20l, 10l) STARLAB, Hamburg, Germany 
Syringes and needles BD Franklin Lakes, USA 
Whatman filter paper 3MM Schleicher & Schuell, Dassel, Germany 
Magnetic rack DynaMag™-2 Magnet Fisher Scientific, Waltham, United States 
PVDF membrane  
EMD Millipore, Burlington, United 
States 
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3.13.3  SOFTWARE AND WEBSITES 
Designation Company 
Adobe CS4/CS6 Adobe, San Jose, USA 
Microsoft Office 2003, 2010 Microsoft, Redmond, USA 
Image Lab™ Software BioRad, Munich, Germany 
Webcutter http://rna.lundberg.gu.se/cutter2 
PaVE https://pave.niaid.nih.gov/ 
BRB-ArrayTools software v4.2 NIH 
Serial Cloner http://serialbasics.free.fr/Serial_Cloner.html 
Human Metabolome Database  http://www.hmdb.ca/ 
METLIN database https://metlin.scripps.edu 
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4 METHODS 
4.1 CULTIVATION AND MANIPULATION OF 
PROKARYOTIC CELLS 
4.1.1 TRANSFORMATION OF BACTERIA BY HEAT SHOCK 
- Put 1 ng of pure DNA or 5 µl of ligation product in 50 l of bacteria 
(DH5)DH5α) or 80 µl (Rosetta) 
- Put the solution for 30 minutes on ice 
- Then 30 seconds at 42°C 
- And again in ice for 2 min 
- Put the bacteria in 300 l of LB without antibiotics and incubate with agitation for 
1 h and 30 min at 37°C 
- Take a rate of 50 l and put in a Petri dish with LB + antibiotic; incubate at 37°C 
overnight 
- Centrifuge the rest of the bacteria, re-suspend in 100 l of LB and put in a Petri 
dish with LB + antibiotic; incubate at 37°C overnight 
Each colony formed originates from a single transformed bacterial cell. Therefore, each 
cell within each colony contains identical plasmid DNA. 
4.1.2 CULTIVATION AND STORAGE OF BACTERIA 
BACTERIAL CULTURE 
- Take a colony with a sterile tip and dissolve it in 6 ml of LB medium with 
antibiotic. 
- Incubate in agitation at 37°C overnight 
- Process the bacteria to purify the plasmid DNA (mini-prep) or 
- Take the pre-inoculum and put it in 200 ml of LB with antibiotic (maxi-prep) 
- Put the culture at 37°C in agitation overnight. 
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LONG TERM BACTERIAL STORAGE 
For long-term storage of verified (sequenced) bacterial clones, 500 µl of a liquid culture 
was transferred to a 2ml cryotube and 500 l of glycerol (100%) were added. The glycerol 
stocks were stored at -80⁰C. 
4.2 CULTIVATION AND MANIPULATION OF 
EUKARYOTIC CELL 
All cell lines were cultivated in an incubator at 37⁰C, 5% CO2 and 90% humidity. 
Passaging of the cells was performed when cells reached around 80% confluency.  
4.2.1 CULTIVATION OF NIH/3T3 FIBROBLASTS 
The fibroblast cells are fast growing cells and every 3/4 days is necessary to split them 
because they became confluent.  
The NIH/3T3 are kept in culture in T75 flasks. 
SPLIT OF NIH/3T3 
- Remove the medium 
- Add 8 ml of DPBS and wash the cells  
- Add 1 ml of trypsin and incubate 1 minute at 37°C 
- Add 9 ml of DMEM +++ to inactivate the trypsin 
- Centrifuge for 3 minutes at 900 rpm 
- Discard the supernatant 
- Re-suspend the pellet into 10 ml of DMEM +++ 
- Put an amount of the re-suspended cells in the flask (the amount depends on the 
dilution). 
4.2.2 CULTIVATION OF PHOENIX 
The Phoenix cells are adherent cells but, unlike the NIH/3T3, they attach to the surface 
poorly. It’ necessary to pay attention while washing the cells and changing the media to 
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avoid the detachment of the cells from the surface of the dish. The protocol of the split 
of the cells is the same used for the NIH/3T3. 
The Phoenix are kept in culture in 10 cm dishes. 
4.2.3 CULTIVATION OF HUMAN KERATINOCYTES (PRIMARY 
AND EXPRESSING E6/E7) 
The human keratinocytes were cultivated with the support of feeder layer (NIH/3T3 
fibroblasts) with a protocol modified from Rheinwald and Green [141]. The cells of the 
feeder layer not only secrete soluble factors into the culture medium but deposit ECM 
molecules on the culturing surface that facilitate attachment and growth of co-cultured 
cells [142]. 
The NIH/3T3 cells added to the human primary keratinocyte are treated with the 
mitomycin to block their proliferation. The feeder layers need to be changed every time 
the keratinocytes are split or every 2/3 days since the NIH/3T3 cells treated with the 
mitomycin die. 
The keratinocytes are kept in culture in T25 flasks. 
PREPARATION OF THE FEEDER (NIH/3T3) 
- Take a flask of NIH/3T3 (around the 80% of confluence), add 250 µl mitomycin 
C and incubate at 37°C for 2 hours 
- Remove the medium 
- Add 3 ml of DPBS and wash the cells 
- Add 1 ml of trypsin and incubate at 37°C for 1 minutes 
- Add 9 ml of DMEM +++ to inactivate the trypsin 
- Centrifuge for 3 minutes at 900 rpm 
- Remove the solution 
- Add 10 ml of FAD 
- Counts the cells 
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CHANGE OF FEEDER LAYER 
- Remove the medium 
- Add 3 ml of DPBS to wash the cells 
- Add 3 ml of DPBS + EDTA and let it acts for 3 minutes. Only the fibroblasts tear 
away from the flask meanwhile the keratinocyte remain adherent to the flask. 
- Remove the solution 
- Add 3 ml of DPBS to wash the cells 
- Remove the solution 
- Add 5 ml of FAD into the flask 
- Add “x” µl of counted NIH/3T3 (for the amount of the NIH/3T3 see the table 1) 
- Mix with a cross movement 
SPLIT OF KERATINOCYTES 
- Remove the medium 
- Add 3 ml of DPBS to wash the cells 
- Add 3 ml of DPBS + EDTA and let it acts for 3 minutes.  
- Remove the solution 
- Add 3 ml of DPBS to wash the cells 
- Remove the solution 
- Add 1 ml of trypsin and incubate at 37°C for 5-7 minutes 
- Add 9 ml of DMEM +++ to inactivate the trypsin 
- Centrifuge for 3 minutes at 900 rpm 
- Remove the supernatant 
- Re-suspend the pellet into the appropriate amount of FAD 
- Add “x” µl of counted NIH/3T3 (for the amount of the NIH/3T3 see the table 1) 
- Mix with a cross movement 
For the maintenance of the culture always split the keratinocytes 1:2. 
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Table 1: Amount of feeder for each type of support. 
Type of support Number of NIH/3T3 cells 
Small flask 2.5 x 105 cells 
Big flask 7 x 105 cells 
6 cm2 dish 1.5 x 105 cells 
10 cm2 dish 5 x 105 cells 
6 wells dish 1 x 105 cells 
4.2.4 CULTIVATION OF HNC136 
The protocol of the split of the cells is the same used for the NIH/3T3 except for the 
incubation time at 37 ⁰C with trypsin, which varies accordingly to the cell type. 
This cells line can be maintained in culture in T75 or T150 flasks. 
HNC136 are usually split 1:2 for maintenance. 
4.2.5 CELLS COUNTING 
- Put 10 µl of re-suspended cells in an Eppendorf 
- Add 10 µl of trypan blue (allows to distinguish the vital from the not vital cells) 
and mix 
- Take 10 µl of the mix and add them to the counting plate 
- Read the concentration of cells in the counting machine (Biorad TC20 ™). 
4.2.6 CRYOPRESERVATION AND THAWING OF MAMMALIAN 
CELLS 
CRYOPRESERVATION 
For cryopreservation, the cells were harvested by trypsinization and centrifuged. After 
centrifugation, the cell pellet was resuspended in 1ml cryomedium and the cell solution 
stored in cryotubes. Freezing of the cells was performed in a slow freeze chamber with 
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isopropanol at -80°C for at least 24h before the cells were transferred to liquid nitrogen. 
Using a container filled with isopropanol allows freezing the cells slowly by reducing the 
temperature at approximately 1°C per minute. When the cells are re-suspended in 
cryomedium put them immediately in the freezer to avoid the death of the cells (DMSO 
is toxic). 
THAWING 
- Take the cryotubes out of liquid nitrogen and thaw the cell solution by keeping in 
the hands (attention: once the cells are thaw, do the next steps immediately) 
- Transfer 1 ml of cells in a falcon and add 10 ml of DMEM +++ 
- Centrifuge at 900 rpm for 3 minutes 
- Discard the supernatant 
- Gently resuspend the pellet in the appropriate medium. 
When thawing the human keratinocytes, prepare in advance the inactivated feeder cells as 
described in paragraph 4.2.3. 
4.2.7 CELL TREATMENTS 
DOXORUBICIN 
- Plate 3.5x105 HFKs cells or HFKs cells expressing E6/E7 of the different HPVs 
in a well of a 6 well plate. Add the appropriate amount of feeder cells. 
- After 24 hours remove the feeder as described in paragraph 4.2.3 and 
- treat the cells with doxorubicin or DMSO 
- collect the cells after 8 hours of treatment; preserve the 2/3 of the pellet in one 1.5 
ml tube for future protein extraction and the remaining 1/3 of the pellet in 
another 1.5 ml tube for future RNA extraction. 
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MG132 
- Plate 3.5x105 HFKs cells or HFKs cells expressing E6/E7 of the different HPVs 
in a well of a 6 well plate. Add the appropriate amount of feeder cells. 
- After 24 hours remove the feeder as described in paragraph 4.2.3 and 
- treat the cells with MG132 or DMSO 
- collect the cells after 4 hours of treatment; preserve the 2/3 of the pellet in one 1.5 
ml tube for future protein extraction and the remaining 1/3 of the pellet in 
another 1.5 ml tube for future RNA extraction. 
CYCLOHEXIMIDE 
- Plate 3.5x105 NIKs pLXSNØ cells or NIKs cells expressing E6/E7 of the 
different HPVs in a well of a 6 well plate. 
- After 24 hours, treat the cells with cycloheximide or DMSO 
- collect the cells after 1, 2, 4 and 6 hours of treatment. 
4.2.8 siRNA KNOCK-DOWN 
- Seed 4x105 HFKs or HFKs expressing E6/E7 in a well of a 6 wells-plate; add the 
appropriate amount of feeder cells. 
- After 24 hours from the seeding, transfect the cells with the same 10 nM of 
scramble or siRNA using Lipo2000. 
- After 6 hours replace the medium with fresh FAD without cholera toxin, 
Penicillin/streptomycin and Ciprofloxacin. 
- After 24 hours replace the medium with complete FAD. 
- After 48 hours from the transfection remove the feeder and collect the cells. 
4.3 RETROVIRUS INFECTION 
The retrovirus infection donor 1 has been performed in Heidelberg in a P2 plus 
laboratory by myself while the retrovirus infection donor 2 and 3 has been performed in 
Lyon in a P3 laboratory by Cecilia Sirand and Gessica Tore.  
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4.3.1 TRANSFECTION 
Two days before transfection seed the Phoenix cells in 10 cm dishes, in this way they will 
be 50/70% confluent the day of the transfection. 
Infect the Phoenix cells with the construct, following the protocol: 
PREPARE THE DNA SOLUTION 
- in a 15 ml Falcon mix the DNA (10 µg) with H2O (to a volume of 440 µl) and 62 
µl of CaCl2 (2M) 
- mix gently 
- add 500 µl of HBS (2X) drop by drop 
- shake with energy the solution 
PREPARE THE PHOENIX CELLS 
- remove the old medium from the Phoenix cell cultures  
- add 5 ml of fresh medium 
- add 5 µl of Chloroquine and gently mix 
ADD THE DNA SOLUTION 
- add the DNA solution drop by drop evenly distributing the solution in the dish 
- transport the cells into the P3 laboratory 
CHANGE MEDIUM 
- after 6/8 hours wash twice the phoenix cells with DPBS 
- add 5 ml of fresh medium. 
CHANGE MEDIUM 
- after 24 hours change the medium without the wash with DPBS 
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4.3.2 INFECTION 
PREPARE RETROVIRAL SUSPENSION 
- Collect medium of the transfected Phoenix cells and pass twice the medium 
through the 0.22 µm filter. 
- Add 5 µl of Polybrene into each retroviral suspension 
INFECT THE PRIMARY KERATINOCYTE 
- Add the retrovirus suspension to the keratinocytes 
- After 3 hours remove the retrovirus suspension 
- Add fresh FAD medium 
4.3.3 SELECTION 
- Split the cells 1:1 and start the selection 24 hours after the infection using the 
neomycin. 
Split 1:1 a flask of HPK not infected and add neomycin; when these cells die, the 
selection is over. 
4.3.4 TEST FOR THE EXIT OF THE CELLS FROM THE P3 
To exit the cells from the P3 it is necessary to prove that the transformed HPK cells do 
not produce viruses and so they are not dangerous anymore. 
- Plate 0.5*105 NIH/3T3 cells in a 6 wells plate for each transformed HFK line 
- add the medium from the transformed HFK on the NIH/3T3 cells 
- start the selection with neomycin 
- When all the NIH cells die the transformed cells can go out of P3. 
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4.4 MOLECULAR METHODS 
4.4.1 PURIFICATION OF PLASMID DNA 
MINI-PREP 
Isolation of plasmid DNA with the NucleoSpin® Plasmid mini prep kit was performed 
from a single bacterial colony previously cultured in 6 ml liquid LB medium containing 
the corresponding antibiotics. The preparation of plasmid DNA was performed 
according to manufacturer´s instructions. 
MAXI-PREP 
Isolation of plasmid DNA with the PureLink™ HiPure Plasmid Filter Maxiprep Kit was 
performed using 200ml LB medium with corresponding antibiotics which were inoculated 
with either 1 ml from a liquid bacterial culture or from a bacterial glycerol stock. The 
preparation of the plasmid DNA was performed according to manufacturer´s instructions 
4.4.2 DNA VISUALIZATION 
AGAROSE GEL ELECTROPHORESIS 
To visualize the DNA or to purify the DNA after digestion, prepare the gel as follow. 
The percentage of agarose depends on the size of the DNA to visualize. 
- In a jar prepare 0.5 g (for a 1% gel) or 0.4 g (for a 0.8% gel) of agarose and add 50 
ml of TAE 1X. 
- Cover the jar with his cap without closing it and put it in the microwave to the 
maximum heating until the agarose is completely melted. 
- Under chemical hood add 1 µl of red gel and mix gently. 
- Assembly the tray with the combs for the wanted number of wells. 
- Pour the prepared solution into the tray and wait until the complete solidification. 
- Remove the combs and put the tray into the electrophoretic system. The TAE 1X 
buffer must submerge completely the agarose gel. 
- Load the samples in the wells. 
- Close the electrophoretic system and set the voltage (85V for 40 minutes). 
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Before application of the DNA samples to the gel, the samples were mixed with 6x DNA 
loading dye in a ratio 1:6. To determine the size of the corresponding DNA fragments, a 
marker was loaded on the gel.  
The DNA fragments were visualized with the ChemiDoc machine. 
4.4.3 MOLECULAR CLONING 
POLYMERASE CHAIN REACTION (PCR) 
The Polymerase Chain Reaction (PCR) was performed to amplify the DNA sequences of 
interest for cloning into selected destination vectors. The DNA sequences were amplified 
using corresponding template DNAs encoding for the sequence of interest. Primers 
needed for the amplification process were generated as described in paragraph 3.5.3 and 
ordered as well as produced at MWG Eurofins, Ebersberg, Germany. Each Primer was 
generated for a specific cloning process, containing different restriction sites. The sites to 
be included in the primer sequence were selected depending on the specific destination 
vector used for later cloning steps. 
All PCRs were performed using the HotStarTaq DNA Polymerase from Qiagen, 
according to the manufacturer´s instructions (table 2 and table 3). The annealing 
temperature (Tm) strongly depends on the primers used for the PCR reaction. 
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Table 2: reaction mix 
 Ci Cf V 
Buffer 10X 1X 2.5 l 
dNTP 10 M 200 M 1 l 
Primer forward 10 M 0,3 M 1.5 l 
Primer reverse 10 M 0,3 M 1.5 l 
HotStartTaq pol 5 U/l 2,5 U/reaction 1 l 
DNA // // 1 l 
H2O // // To volume 
   25 l 
Table 3: Standard PCR program 
Temperature Time  
95 °C 15 min  
94 °C 1 min 
35 cycles 
Tm 1 min 
72 °C 
1 min/kb of DNA to 
extend 
72 °C 10 min  
4 °C ∞  
PCR PURIFICATION 
For the purification of the fragment of DNA obtained from PCR, the QIAquick PCR 
Purification Kit from Qiagen was used. The purification procedure was carried out 
according to the manufacturer´s instructions. The DNA was eluted in 10 µl. 
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ENZYMATIC RESTRICTION OF PCR PRODUCTS 
To prepare the PCR product for ligation into the target vector, the PCR products were 
doubled digested with the appropriate restriction enzymes. NEB restriction enzymes were 
used with CutSmart buffer after the compatibility for double digestion was checked on 
the NEB website. A mix was prepared as in table 4 and the samples were incubated at 
37°C for 1 hour. 
Table 4: standard PCR product digestion mix 
 Ci Cf Vi 
PCR amplified fragments // // 10 µl 
Cut Smart Buffer 10X 1X 2 µl 
Restriction enzyme 1 10 U/µl 0.27 U/µl 0.8 µl 
Restriction enzyme 2 10 U/µl 0.27 U/µl 0.8 µl 
H2O // // To volume 
   20 µl 
ENZYMATIC RESTRICTION OF VECTOR 
To prepare the vector for ligation with the insert, the vector was doubled digested with 
the appropriate restriction enzymes. NEB restriction enzymes were used with CutSmart 
buffer after the compatibility for double digestion was checked on the NEB website. A 
mix was prepared as in table 5 and the samples were incubated at 37°C for 1 hour. 
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Table 5: standard vector digestion mix 
 Ci Cf 
Volume per 
reaction 
Vector // 0,1 µg/µl // 
Cut Smart Buffer 10X 1X 3 µl 
Restriction enzyme 1 10 U/µl 0.4 U/µl 0.8 µl 
Restriction enzyme 2 10 U/µl 0.4 U/µl 0.8 µl 
H2O // // To volume 
   20 µl 
GEL EXTRACTION 
For purification of specific DNA fragments after enzymatic restriction, the QIAquick Gel 
Extraction Kit from Qiagen was used. After the DNA fragments were separated by 
agarose gel electrophoresis (paragraph 4.4.2), DNA was visualized with the help of a 
254nm UV-light to excise the corresponding part of the gel for purification. The 
following purification procedure was carried out according to the manufacturer´s 
instructions. 
LIGATION 
The ligation mix was according to manufacturer´s instruction from Roche (see table 6). 
Vector DNA and insert were used in a molar ratio of 1:3. The ligation mix was either 
incubated at 16°C overnight. 
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Table 6: ligation standard mix. 
 Volume per reaction 
Vector DNA X l 
Insert DNA Y l 
T4 DNA ligase 1 l 
Buffer 10X 2 l 
H2O To volume 
 20 l 
BACTERIAL TRANSFORMATION AND PLASMID DNA EXTRACTION 
After the ligation, 5 l of the ligation mix was used to transform E.coli bacteria as 
described in paragraph 4.1.1. The following day 5 colony of each transformation were 
incubated in 6 ml of LB with the appropriate antibiotics. The plasmid DNA was extracted 
using a NucleoSpin® Plasmid mini prep kit to be analyzed via analytic digestion. 
ANALYTIC DIGESTION 
To test isolated plasmid DNA for the absence or presence of a specific insert, 5l of the 
DNA sample were used. For enzymatic restriction a master mix was prepared as in table 7 
and the samples were incubated at 37°C for 1 hour. To analyze the restricted plasmid 
DNA, the digestion products were loaded on a agarose gel and visualized with the 
ChemiDoc machine. 
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Table 7: analytic digestion mix. 
 Ci Cf V 
PCR amplified fragments // // 5 µl 
Cut Smart Buffer 10X 1X 2 µl 
Restriction enzyme 1 10 U/µl 0.1 U/µl 0.2 µl 
Restriction enzyme 2 10 U/µl 0.1 U/µl 0.2 µl  
H2O // // To volume 
   20 µl 
SEQUENCING 
Among the clones analyzed through mini prep and sub-sequential analytical digestion, 
only the ones with the insert were sent to sequencing to confirm the identity of the insert 
and the correctness of the sequence. All the sequences have been sent to and analyzed by 
GATC Biotech AG.  
SITE DIRECTED MUTAGENESIS 
For the site directed mutagenesis the “QuikChange Lightning Site-Directed Mutagenesis 
Kit” by Agilent Technologies was used. The manufacturer protocol was followed and for 
each mutant 100 ng of dsDNA template was used. 
4.4.4 RNA MANIPULATION 
RNA EXTRACTION 
For the RNA extraction, the kit “NucleoSpin® RNA” by Macherey-Nagel has been used, 
following the manufacturer’s instruction. To avoid degradation of RNA, keep the samples 
in ice until retro-transcription. The RNA concentration has been measured using the 
Nano-Drop machine. 
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RETRO-TRANSCRIPTION 
For the retro-transcription, the kit “RevertAid H Minus Reverse Transcriptase” by 
Thermo Scientific has been used. After the extraction of the RNA the following protocol 
has been followed: 
- Prepare the mix as table 8: 
- Mix gently and centrifuge briefly 
- Incubate at 70 °C for 5 minutes, then put in ice and centrifuge briefly 
- With the samples in ice add the reagents as table 9: 
- Mix gently and centrifuge briefly 
- Incubates 5 minutes at room temperature 
- Add the 1 µl of retro-transcriptase enzyme 
- Incubate 10 minutes at 25°C, 1 hour at 42°C and 10 minutes at 70°C. 
Table 8: RNA-primer mix. 
RNA (800 ng) X µl 
Primer random 1 µl 
H2O To volume 
 12 µl 
Table 8: dNTPs mix. 
Buffer 5X 4 µl 
Riboblock inhibitor 1 µl 
dNTP  2 µl 
REAL TIME RETRO-TRANSCRIPTASE PCR (REAL TIME RT- PCR) 
- Prepare the mesa green mix as in table 9 (for each sample of each couple of 
primers): 
- Vortex the mix and briefly centrifuge it 
Methods 
  
67 
 
- Prepare the cDNA mix as in table 10 (for each sample of each different DNA 
sample): 
- Vortex the mix and briefly centrifuge it 
- Add the mesa green mix to the plate wells 
- Add 9.2 of the cDNA mix to each well 
- Close with the proper plastic foil 
- Briefly centrifuge the plate 
- Put the plate in the qPCR machine and set the program as in table 11:  
Table 9: Mesa green mix. 
Mesa green  10 µl 
primer forward (10 µM) 0.4 µl 
primer reverse (10 µM) 0.4 µl 
Table 10: cDNA mix. 
H2O 6.7 µl 
cDNA 2.5 µl 
Table 11: Standard Real time RT-PCR program. 
Temperature Time  
95 °C 10 min  
95 °C 15 s 
45 cycles 60 °C 45 s 
72 °C 45 s 
95 °C 1 min  
55 °C 30 s  
95 °C 30 s  
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4.5 PROTEIN ANALYSIS 
4.5.1 PROTEIN EXTRACTION 
During the protein extraction the pellet, the IP solution and the proteins were always kept 
on ice to avoid degradation. An adequate amount of IP buffer (paragraph 3.6.2) was used 
to re-suspend the pellet. After incubation on ice for 30 minutes, the lysate has been 
centrifuged at 13000 rpm and the supernatant collected and used for further analysis or 
stored at -20 °C. 
4.5.2 DETERMINATION OF PROTEIN CONCENTRATION BY 
BRADFORD ASSAY 
To determine the concentration of protein of a specific sample, a BSA calibration curve 
was generated by titration. Therefore a 10 g/l BSA stock solution was diluted in H2O 
to get a final concentration of 2 g/l BSA. From this BSA dilution a 1:2 dilution series 
was prepared up to 0.125 g/l . The BSA dilutions were analyzed with the Bradford 
Assay and a curve of concentrations and absorbance values was generated. 
Following the preparation of the calibration curve, the samples were analyzed: 
- For each sample prepare 2 ml of reagent A + 40 µl of reagent B 
- Prepare also a “blank” sample without protein 
- Mix and add 1 ml in a cuvette for protein 
- Add 5 µl of protein extract 
- Add another 1 ml of reagents mix to the cuvette 
- Incubate at 37 °C for 30 minutes 
- Read the OD at the spectrophotometer at 562 nm wavelength 
4.5.3 LAMBDA PROTEIN PHOSPHATASE (PP) TREATMENT. 
The lambda protein phosphatase enzyme detaches the phosphoryl group from the 
phosphorylated serine, threonine and tyrosine residues of a protein. To 20 µg of protein 
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extract, 1 µl of NEB “Lambda Protein Phosphatase (Lambda PP)” and the appropriate 
amount of buffer were added. The reaction mix was incubated for 30 minutes at 30°C. 
4.5.4 ACRYLAMIDE GEL 
SDS-polyacrylamide gels were prepared by combining two kinds of gels with different 
pore size and pH, the stacking gel (3% polyacrylamide, pH 6.8) and the running gel 
(percentage of polyacrylamide depending on the experiment, pH 8.8). After the 
polymerization of the SDS polyacrylamide, the ready-to-use gel was placed into the 
destined running system and the 1X running buffer was added. 
Twenty µg of protein samples were prepared by adding 6X loading buffer (containing 
SDS and -mercaptoethanol) and water to a final volume of 20 µl. The samples were 
denaturized at 95°C for 10min. 
The samples were loaded into the wells of the SDS polyacrylamide gel and 5 l of a 
protein ladder was loaded into a well for use as size standard. Until the proteins reached 
the interface of stacking gel to separation gel the power was set to 80V and increased 
afterwards to 120V for separation of the proteins according to their molecular weight. 
4.5.5 WESTERN BLOT ANALYSIS 
TRANSFER 
For western blot analysis, the proteins had to be transferred from the SDS-polyacrylamide 
gel to the PVDF (Polyvinylidene fluoride) membrane, where the proteins could be 
analyzed by specific antibody detection. The hydrophobicity of PVDF makes it an ideal 
support for binding proteins in electrophoretic blotting applications. Because of the 
hydrophobic nature of PVDF, it does require a pre-wetting step in methanol of 15 
seconds. PVDF is resistant to solvents and, therefore, these membranes can be easily 
stripped and reused to look at other proteins. 
After the activation of the PVDF membrane in methanol, the transfer “sandwich” has 
been prepared as in figure 12 The transfer method is “wet”, therefore the preparation of 
the “sandwich” has been performed in a tray with 1X transfer buffer. 
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To increase the efficiency of the transfer, the transfer buffer was maintained cold with a 
cooling unit and through continuous stir. The transfer was then performed at 120mA/per 
gel for 90 min to ensure an adequate transfer of all proteins to the membrane. 
 
Figure 12: Layers of the transfer sandwich. The proteins in the SDS-page are negatively 
charged and transfer from the negative to the positive pole. The gel is position close to the 
negative pole and the activated PVDF membrane is laid above the gel, close to the positive pole. 
Three layers of Whatman paper are positioned at the extremities of the sandwich to protect the 
PVDF membrane and the gel. 
MEMBRANE BLOCKING 
After the transfer of the protein from the gel to the membrane, to block remaining 
protein binding sites on the PVDF membrane, the membrane was incubated in 10% skim 
milk dissolved in PBS-tween at room temperature for 1h incubate. 
PRIMARY ANTIBODY 
The primary antibody solution, directed against the protein of interest, was prepared with 
5% skim milk in PBS-tween. The antibody dilution was decided following the 
manufacturer’s instruction (usually 1:1000 dilutions). 
After a brief wash of the membrane with PBS-tween, the primary antibody solution has 
been incubated overnight at 4 °C on the rocking platform shaker. 
SECONDARY ANTIBODY 
After incubation with the primary antibody, excess antibody was removed by washing the 
membrane three times with PBS-tween for 10min. The corresponding secondary antibody 
conjugated with horse reddish peroxidase (HRP) was diluted 1:2000 in 5% skim milk in 
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PBS-tween and added to the membrane at room temperature for 1h. The previously 
described washing steps were repeated after incubation of the secondary antibody to 
remove unbound antibody from the membrane. 
DEVELOP 
For detection of the proteins solution A, containing luminol plus enhancer and solution 
B, a peroxide solution of the chemiluminescence kit (paragraph 3.6.5) were mixed in a 1:1 
ratio and the membrane was incubated in the substrate solution for 1min. The position of 
the bound secondary antibody and therefore indirectly the protein of interest were 
visualized using a Chemidoc machine. 
STRIPPING 
The removal of primary and secondary antibodies from a western blot membrane is 
useful when one wants to investigate more than one protein on the same blot. After the 
wash of the membrane at room temperature for 15 minutes in PBS-tween, the membrane 
was incubated with the stripping solution (Paragraph 3.6.5) at room temperature for 15 
minutes. The membrane was then washed with PBS-tween and re-activated with a brief 
passage in methanol. After a wash with PBS-tween, the membrane was blocked with milk 
10% for 1h at room temperature. 
4.6 MALTOSE BINDING PROTEIN (MBP) PULLDOWN 
4.6.1 PREPARATION OF BEADS 
PRODUCTION OF FUSION PROTEINS 
The fusion proteins have been produced in E. coli Rosetta, a strain engineered to produce 
recombinant proteins. The following protocol has been used:  
- Transform E.coli Rosetta cells and plate on agarose LB+ kan dishes 
- Grow the bacteria in LB+KAN till the OD600 of 0.6 
- Collect 1 ml of “Not Induced” bacteria 
- Add 0.5 mM of IPTG and grow the cells for 2 hours at 37°C 
- Collect 1 ml of “Induced” bacteria 
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- Harvest the cells by centrifugation 
- Centrifuge the “induced” and “not induced” bacteria, remove the supernatant and 
resuspend in 100 µl of Laemmli loading buffer. Load on a SDS-page to see the 
production of the fusion proteins 
PRODUCTION OF MAGNETIC BEADS WITH FUSION PROTEINS 
To obtain magnetic beads with the fusion proteins that can be used later for the 
pulldown, the lysate from the induced bacteria was incubated with amylose magnetic 
beads. The following protocol has been used: 
- Re-suspend the pellet in 1 ml MBP buffer 
- Disrupt the cells by sonication (in ice) 
- Centrifuge for 30 min at 4°C at 5000 rpm 
- incubate the supernatants with 50 l of amylose magnetic beads for 1 h at 4°C 
- wash 8 times with MBP buffer  
- store the beads in 10 µl aliquots 
4.6.2 CELL EXTRACT PREPARATION 
The cells of interest were harvest and lysate with an appropriate amount of IP lysis buffer 
and the protein concentration was measured with the Bradford Assay. 
4.6.3 PULLDOWN 
PRE-CLEARING 
A pre-clearing step was performed to decrease the non-specific binding of the cell 
proteins to the maltose binding protein. The cell protein extract was incubated at 4°C for 
1 hour on a rotating wheel with 10 µl of MBP-GFP beads. 
INCUBATION 
10 µl immobilized maltose binding protein (MBP) fusion proteins were incubated with 
600 µg of pre-cleared protein for 2h at 4 °C. After the incubation 8 washes with MBP 
buffer were performed to remove all the not-bound proteins. 
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4.6.4 WESTERN BLOT 
After the washes, the beads were re-suspended in 15 µl of Laemmli buffer and denatured 
for 10 min at 95°C. The beads, as well as 5 µl of input cell lysate, have been loaded on 
SDS-polyacrylamide gel and a western blot has been performed as described in paragraph 
4.5.5. In addition, the membrane has been stained with Red Ponceau for the identification 
of the fusion proteins. 
4.7 MICROARRAY-BASED WHOLE GENOME 
EXPRESSION PROFILING AND DATA ANALYSIS 
The micro array experiment was performed by Genetic Cancer Susceptibility Group at 
IARC (Lyon, FR). The analysis of the micro array data was performed in collaboration 
with the bio-informatician of Infection and Cancer Biology group (Lyon, FR).  
4.7.1 RNA QUALITY CONTROL 
RNA concentration and purity were evaluated with the Nanodrop® (Thermo Scientific). 
RNA integrity and quantification were characterized by measuring the 28s/18s rRNA 
ratio and RIN (RNA Integrity Number) using the Agilent 2100 bioanalyzer instrument 
and the RNA 6000 Nano kit. The RIN software classifies the integrity of eukaryotic total 
RNAs on a scale of 1 to 10, from most to least degraded. 
4.7.2 MICRO ARRAY 
Genome-wide gene expression profiling analysis was performed on Illumina HumanHT-
12 v4 Expression BeadChips (24,000 annotated genes covered). Candidate probe 
sequences included on the HumanHT-12 v4 Expression BeadChip derived from the 
NCBI RefSeq (Build 36.2, Rel22) and the UniGene (Build 199) databases. Using the 
Illumina TotalPrep RNA Amplification Kit (Ambion®), 500 ng of extracted RNAs were 
converted to cDNAs and subsequent biotin labelled single-stranded cRNAs. The 
distribution of homogeneous in vitro transcription products (cRNAs) was checked with 
the Agilent 2100 bioanalyzer instrument and the RNA 6000 Nano kit. 750 ng of biotin 
labelled cRNAs of the 7 samples (including 2 controls) were hybridized overnight to 4 
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HumanHT-12 Expression BeadChips. Subsequent steps included washing, streptavadin-
Cy3 staining and scanning of the arrays on an Illumina BeadArray Reader. The Illumina 
Genome Studio V2010.2 was used to obtain the signal values (AVG-Signal), with no 
normalization and no background subtraction. Data quality controls were performed 
using internal controls present on the HumanHT-12 beadchip and were visualized as a 
control summary plot and for each sample as noise-to-signal ratios calculated by P95/P05 
signal intensities. All samples had P95/P05 >10, defined as sample quality threshold 
The microarray experiments are MIAME compliant and have been deposited at the 
NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) 
under accession GSE100681. 
4.7.3 DIFFERENTIAL EXPRESSION ANALYSIS 
Differential expression analysis was performed using BRB-ArrayTools software v4.2. The 
raw signal intensities of all samples were log-transformed and quantile normalized without 
background subtraction with the exclusion of any probe showing excess dispersion 
(defined by more than 85% of individual probe values differing from the median by more 
than 1.5-fold). Class comparison for Microarray Analysis using the t-test method was 
performed for identification of differentially expressed probes. Probes with a p-value of < 
0.001, with a minimum of 1.5-fold change and a False Discovery rate (FDR) of <0.01 
were considered significantly differentially expressed. The different condition was then 
hierarchically clustered (complete-linkage clustering) based on the Pearson distance of the 
log2 fold change value for each gene 
4.7.4 HEATMAP 
The heatmap was generated with the use of "heatmap.2" function available under "gplots" 
package version 3.0.1 with R version 3.4.3. 
The different conditions were hierarchically clustered (complete-linkage clustering) based 
on the Pearson distance of the log2 fold change value for each gene. 
Methods 
  
75 
 
4.7.5 PATHWAY ANALYSIS 
The genes de-regulated in each condition were analyzed for pathway enrichment using the 
Erinchr software and the KEGG database (2016 version) was used as annotated gene set. 
The results were ranked based on the combined score and represented in histograms.  
4.7.6 COMPARATIVE ANALYSIS 
The genes de-regulated in each 3 expressing HFKs were compared to the genes de-
regulated in HPV16 and HPV38 expressing HFKs using Venny software 
(http://bioinfogp.cnb.csic.es/tools/venny/). From the number of genes shared between 
each 3 type and HPV16 or HPV38 a percentage of shared genes was calculated. 
4.8 LC/MS SUPERNATANT ANALYSIS 
4.8.1 SAMPLE PREPARATIONS 
The samples were filtering the precipitate with 0.2 m Captiva ND plates (Agilent 
Technologies) into a polypropylene well plate. The plate was then sealed with a Rapid 
EPS well plate sealing tape (BioChromato) and kept at 4°C until analysis. Quality control 
(QC) samples were prepared from a pool created from small aliquots of all study samples. 
4.8.2  ANALYTICAL METHODS AND INSTRUMENTATION 
All of the samples were analyzed by mass spectrometry (MS) by using a 6550 quadrupole 
time-of-flight mass spectrometer coupled to a 1290 Infinity UHPLC system (Agilent 
Technologies).  
Analysis of the sample batch was initiated with 10 priming injections of the QC sample to 
achieve a stable instrument response. Study samples were injected in a randomized order, 
and the same QC sample was injected every 10 samples to monitor instrument 
performance and sample stability over the course of the entire data acquisition. The same 
batch of samples was successively analyzed by reversed-phase (RP) chromatography. The 
RP analysis was performed on a Waters Acquity UPLC HSS T3 column (1.8 m, 2.1 × 
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100 mm) at 45°C. A flow rate of 0.4 mL/min was used with a linear gradient of 0.05% 
formic acid in water (eluent A) and 0.05% formic acid in methanol (eluent B). The 
gradient profile was as follows: 5–100% eluent B from 0 to 6 min and 100% eluent B 
from 6 to 10.5 min, followed by a 2-min equilibration with 5% eluent B.  
 The mass spectrometer was operated in positive electrospray ionization (Pos) mode with 
the use of the following conditions: drying gas (nitrogen) temperature, 175°C; drying gas 
flow rate, 12 L/min; sheath gas temperature, 350°C; sheath gas flow rate, 11 L/min; 
nebulizer pressure, 45 pounds/square inch; capillary voltage, 3500 V; nozzle voltage, 300 
V; and fragmentor voltage, 175 V. Data acquisition was performed by using a 2-GHz 
extended dynamic range mode across a mass range of 50–1050 m/z. The scan rate was 
1.67 Hz, and data acquisition was in centroid mode. Continuous mass axis calibration was 
performed by monitoring 2 reference ions from an infusion solution throughout the runs 
(m/z 121.050873 and m/z 922.009798). Data were acquired by using MassHunter 
Acquisition B.05.01 (Agilent Technologies).  
4.8.3  RAW DATA PREPROCESSING AND FILTRATION 
 Preprocessing of the acquired data was performed by using MassHunter Qualitative 
Analysis B.06.00, DA Reprocessor, Mass Profiler Professional 12.1 and Profinder B 06.00 
software (Agilent Technologies). Recursive feature extraction was used to find 
compounds as singly charged proton adducts [M+H]+. Initial data processing was 
performed by using MassHunter Qualitative Analysis with a Molecular Feature Extraction 
algorithm set to small molecules. Threshold values for mass and chromatographic peak 
heights were set to 1500 and 10,000 counts, respectively. Two mass peaks were required 
for a molecular feature, and the peak spacing tolerance for grouping of isotope peaks was 
0.0025 m/z + 7 parts per million (ppm), with the isotope model set to common organic 
molecules. Data were filtered to keep MS features, which were matched to metabolites in 
either the Human Metabolome Database or the METLIN database on the basis of their 
accurate mass (±10 ppm mass error), and only retain features that may be more easily 
identified in subsequent analyses. 
Results 
  
77 
 
5 RESULTS 
5.1 IN VITRO TRANSFORMING ABILITIES OF 3 HPV 
E6 AND E7 PROTEINS  
As a first step of the experimental activities, the transforming abilities of E6 and E7 
derived from the four 3 HPV types (HPV49, 75, 76 and 115) were evaluated in HFK 
cells. 
 
Figure 13: Schematic representation of HFKs cellular fate in the absence or presence of 
E6 and E7. In monolayer culture, the HFKs enter senescence and eventually die after 
approximately 10-12 PDs. In the presence of E6/E7 from different HPV types, cells either enter 
into senescence and die or have a prolonged lifespan that can ultimately lead to the 
immortalization of the keratinocytes. The prolongation of the lifespan requires alteration of 
different cellular pathways such as p53, pRb and hTERT. 
In vivo, keratinocytes located at the basal layer are able to maintain a stem cell-like property 
while the keratinocytes located in the parabasal layers commit to a differentiation program 
and gradually exit from the cell cycle. In an ex-vivo setting, such as monolayer culture, the 
lifespan of HFKs is limited to around 10-12 Population Doubling (PDs). After this brief 
period of time, the cells enter into senescence and eventually die by autophagic 
programmed cell death [143]. The senescent cells can be recognized under the 
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microscope by their characteristic appearance: 5- to 100-fold larger size than young cells, 
numerous dense particles that are probably protein aggregates and several vacuole-like 
structures of various sizes [143, 144].  
Many studies have shown that stable expression of E6 and E7 from certain HPV types 
such as HPV16 leads to an extension of HFK lifespan and immortalization. This behavior 
is schematically shown in Figure 13.  
In the context of a natural infection, the E6 and E7 ORFs are transcribed as a single 
polycistronic mRNA. To accurately mimic this in the tissue culture setting, the 3 
genome fragment covering the two entire ORFs was cloned into the retroviral vector 
pLXSN. In addition to the four 3 HPV types, the E6 and E7 proteins from HPV16, 
which are known to immortalize cells in vitro, were included as a positive control. The 
retroviral expression system was chosen to minimize possible artifacts due to ectopic 
expression of viral proteins. Indeed, in the retroviral vector pLXSN, the two potential 
onco-proteins are expressed under the control of a weak promoter. In addition, retroviral 
transduction results in a single-copy integrant into the host cell, avoiding high expression 
of E6 and E7. To produce recombinant retroviruses, the different pLXSN constructs 
were transfected into the packaging cell line Phoenix, as described in the chapter 
“Methods”. The pLXSN vector expresses a neomycin-resistance marker under the 
control of an independent promoter. Therefore, the retro-transduced HFKs were selected 
using media supplemented with neomycin. The expression of the E6/E7 polycistronic 
transcript was determined by RT-PCR. As shown in Fig. 14, the HPV76 E7 PCR primers 
also amplify HPV49 and 75 mRNA, possibly due to genome similarities within the 3 
species. On the contrary, primers for HPV49, 75 and HPV115 showed high specificity 
and only amplified the intended target sequence (Fig. 14). To confirm that the 
immortalized HFKs expressed the specific 3 HPV genes and no cross-contamination of 
the different HFK lines occurred during long term culture, additional analysis was 
performed at various stages during the long term experiment. DNA from the different 
cell lines was extracted and the E6/E7 region amplified using universal primers (designed 
on the plasmid). The resulting PCR product was then sent for sequencing. The results 
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obtained from the sequencing showed that all the cell lines contained the correct plasmid 
at all the time points (data not shown). 
 
Figure 14: Transduced HFKs express the correct polycistronic E6/E7 mRNA. Total RNA 
was extracted from HFKs transduced with the indicated retroviruses and subject to retro-
transcription to form cDNA. PCR was performed using the indicated cDNA template with 
HPV-specific primers or the corresponding vector preparation as a positive control (C+). 
The immortalization assay was performed on HFKs from three different donors, in order 
to assess the eventual effect of the genetic background of the donor on the 
immortalization abilities and the biological properties of E6 and E7.  
In the first and second donor, expression of HPV49 and 76 E6/E7 proteins induced the 
continuous growth of the HFKs, which have now reached more than 100 PDs, as shown 
in figure 15A and Table 12. By contrast, HPV115 E6/E7-transduced HFKs were only 
able to proliferate for a few PDs and died approximately at the same time of the HFKs 
transduced with empty pLXSN (donor 1), or at the end of the drug selection process 
(donors 2 and 3) (Fig. 15A and Table 12). Interestingly, HPV75 E6/E7 HFKs from 
donor one appeared to proliferate less than HPV49 and 76 E6/E7 HFKs derived from 
the same donor background and only reached approximately 60 PDs, despite being in 
culture for the same amount of time (Fig. 15A and Table 12). However, no difference was 
observed in the proliferation rate of HPV49, 75 and 76 E6/E7 HFKs from donor 2 
(Table 12), suggesting that, at least for HPV75 E6/E7, the efficiency in promoting cellular 
proliferation may be influenced by the genetic background of the donor. HFKs from the 
third donor was cultured for a number of days not sufficient to draw a conclusion about 
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the immortalization abilities. Moreover, HFKs from a fourth donor expressing E6 and E7 
from HPV76 was generated and kept in culture for 60 PDs (data not shown). As shown 
in figure 15A, HFKs expressing HPV16 E6/E7 grow continuously and reach 
immortalization with a higher proliferation rate compared to HPV49 or HPV76 E6/E7 
expressing keratinocytes.  
 
Figure 15: Stable expression of 3 E6/E7 proteins have different outcomes on the 
lifespan of primary keratinocytes. (A) Growth curve of human foreskin keratinocytes (donor 
1) expressing E6/E7 from the indicated HPVs. (B) Morphology of human foreskin keratinocytes 
transduced with the indicated recombinant retroviruses at the indicated PDs. The elongated cells 
visible in the microphotographs are NIH/3T3 fibroblasts. The same magnification was used for 
all the microphotographs (20X). 
In line with the low proliferative rate, the microphotographs in figure 15B show that 
HPV115 E6/E7 HFKs displayed features of arrested and senescent cells, such as irregular 
shape, intercellular bridges and large and multi-nucleated cells. By contrast, HFKs 
expressing the E6/E7 proteins of the other 3 HPV types, as well as of HPV16, showed 
the typical morphology of highly proliferative cells characterized by small size, high 
brightness and regular shape (Fig. 15B). 
As HFKs expressing HPV115 E6/E7 had a reduced lifespan in all donor backgrounds, it 
was not possible to include them in the downstream analysis, shown in the following 
paragraphs.  
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Table 12: Immortalization abilities of 3 types E6/E7 in three different donors. E6 and E7 
from 3 HPV differentially affect the cell growth ability when retro-transduced in primary 
keratinocytes. Population doublings (PD) reached to date by the indicated keratinocytes (from 3 
different donors) stably expressing E6 and E7 of 3 HPVs or carrying the empty retroviral 
vector (pLXSNØ). (*Not Done) 
Retrovirus Donor 1 Donor 2 Donor 3 
pLXSNØ Dead at 1 PD Dead at 1 PD Dead at 1 PD 
pLXSN(E6/E7)HPV49 
108 PD 
(immortalized) 
102 PD 
(immortalized) 
5 PD 
pLXSN(E6/E7)HPV75 63.5 PD 
101 PD 
(immortalized) 
ND* 
pLXSN(E6/E7)HPV76 
101 PD 
(immortalized) 
101 PD 
(immortalized) 
6 PD 
pLXSN(E6/E7)HPV115 Dead at 7.5 PD Dead at 1 PD Dead at 1 PD 
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5.2 3 TYPES 49, 75 AND 76 E6/E7 EFFICIENTLY 
ALTER CELL CYCLE-RELATED PATHWAYS 
5.2.1  pRb PATHWAY IS ALTERED IN 3 HPV E6/E7 HFKs  
The extension of lifespan and immortalization of primary cells are intimately linked to the 
deregulation of the cell cycle. Many previous studies showed that E7 from different  and 
 types are able to inhibit the pRb pathway, promoting unscheduled S-phase entry (see 
chapter 1). 
A previous study focusing on 3 type 49 showed that this E7 can inactivate pRb via 
hyper-phosphorylation (see paragraph 1.2.3) [138]. This mechanism is different from the 
one used by HPV16 E7, which binds pRb and leads to its degradation by proteasome 
pathway (see paragraph 1.2.1).  
As there appears to be a difference in the mechanism used by HPVs to inactivate the pRb 
pathway, the status of pRb in HFKs expressing E6/E7 from 3 HPV types 49, 75 and 76 
was determined. As shown in figure 16A, HPV49, 75 and 76 E6/E7 HFKs have high 
levels of total pRb compared to both control cells (HFKs) and HPV16 E6/E7 HFKs. 
Immunoblotting using a specific antibody against pRb phosphorylated at Serine795 ( pRb 
Ser795) showed a band in all the analyzed 3 types but not in control HFKs or HPV16 
E6/E7 expressing HFKs (fig. 16A). To further prove the phosphorylation status of pRb, 
protein, extracts of control HFKs or E6/E7 expressing HFKs were treated with lambda 
protein phosphatase (-PP) for 30 minutes. -PP is a Mn2+-dependent protein 
phosphatase that releases the phosphate group from phosphorylated serine, threonine and 
tyrosine residues. After -PP treatment, the band corresponding to the phosphorylated- 
pRb was no longer visible for all the 3 types (fig. 16A). Thus, all these three 3 HPV 
types are able to promote pRb phosphorylation, while in HPV16 E6/E7 HFKs, as 
expected, pRb was not detectable in both the total or phosphorylated (Ser795) forms. The 
experiment was repeated three times in cells derived from two different donors (data not 
shown), and slight differences in the efficiency in promoting pRb phosphorylation were 
detected; these differences are most likely due to the different proliferative status of the 
cell cultures. However, in all experiments, the band detected with the antibody against 
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phosphorylated pRb (Ser795) was considerably higher in abundance than the one detected 
in the control HFKs. 
 
Figure 16: 3 E6/E7 proteins alter pRb function in cell cycle control. (A) Protein extracts 
from HFKs or from those expressing E6/E7 of the indicated HPV types were incubated for 30 
minutes at 30°C in presence or absence of lambda phosphatase (-pp). Samples were analyzed by 
immunoblotting using total pRb, phosphorylated pRb (Ser795), and -actin antibodies. (B) Retro-
transcribed total RNA was used as a template for real-time PCR with primers specific for cdc2, 
cdk2 gene or GAPDH. Cdc2 and cdk2 expression levels were normalized to GAPDH levels. The 
result shown in the histogram is the mean of a total of six independent experiments performed in 
keratinocytes from two independent donors. (C) Protein extract from HFKs or transduced HFKs 
expressing E6/E7 of the different 3 types were analyzed by immunoblotting using cdc2, cyclin 
A and -actin antibodies. 
As mentioned in chapter 1, the destabilization of pRb, either through degradation or 
phosphorylation, results in the release of E2F1-DP complex, which in turn induces the 
expression of genes encoding positive regulators of cell cycle, such as cdc2 and cyclin A 
[65, 66]. Accordingly, an increase in the mRNA levels of cdc2 and cdk2 was observed in 
HFKs expressing E6/E7 from 3 types as well as HPV16, compared to control HFKs 
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(pLXSNØ) (fig. 16B). Reflecting the higher rate of growth of HFKs expressing E6/E7 
from HPV16 (fig. 15A) compared to 3 E6/E7 HFKs, higher level of cdc2 and cdk2 
mRNA levels were observed in HPV16 E6/E7 HFKs in comparison to the 3 HFKs 
(fig. 16B). Moreover, the protein levels of the two cell cycle effector proteins cdc2 and 
cyclin A (CycA) were assessed by immunoblotting (fig. 16C). In line with the mRNA level 
shown in figure 16B, the protein level of cdc2 was detectable at higher level with a 
specific antibody in the cells expressing E6/E7 from HPV16 and all the 3 types when 
compared to the HKFs expressing the empty vector (pLXSNØ) (fig. 16C). Another gene 
regulated predominantly by the E2F complex is cyclin A, a cyclin associated with the 
passage of the transition point between G1 and S phase. As seen in figure 4C, CycA 
protein levels were higher in HKFs expressing E6/E7 when compared to control HFKs. 
This data indicates that the cells are indeed in active proliferation.  
5.2.2 p16INK4a PATHWAY IS ALTERED IN 3 HPV E6/E7 HFKs  
Previous studies showed that the cell cycle deregulation mediated by HR HPV16 onco-
proteins is associated with an accumulation of the cell cycle inhibitor p16 INK4a [81]. This 
event appears to be specific for the alpha HR HPV types since HFKs immortalized by 2 
HPV38 E6 and E7 do not express p16 INK4a (unpublished data). 
Therefore, the levels of p16 INK4a were determined in HFKs expressing E6/E7 from 
HPV16 as a positive control, HPV38 as a negative control alongside the 3 HFKs (fig. 
17A and 17B). As shown in the immunoblot in figure 17A, accumulation of p16 INK4a was 
detected in HFKs expressing HPV49, 75 or 76 E6/E7 (fig. 17A) compared to control 
HFKs. However, p16 INK4a accumulation was much higher in HPV16 E6/E7 expressing 
HFKs than in those expressing the 3 E6/E7 proteins (fig. 17A and 17B). The 
differences between HPV16 and the 3 types in p16 INK4a accumulation reflect the 
differences in efficiency in altering the expression of cell cycle regulators (such as cycA 
and cdc2), shown in figure 16B and 16C. In addition, p16INK4a signal was not detected in 
the HPV38 E6/E7 expressing cells, confirming the previous observation and indicating 
that 2 and 3 HPV types interfere with the cell cycle by distinct mechanisms. 
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Figure 17: 3 E6/E7 proteins promotes p16INK4a accumulation in primary keratinocytes. 
(A) Protein extracts from HFKs or transduced HFKs expressing E6/E7 of the different 3 types 
were analyzed by immunoblotting using p16INK4a and -actin antibodies. (B) Band intensities were 
quantified, normalized to -actin levels, and then displayed relative to the control HFK cells. 
Data shown represented five independent experiments performed in two independent 
keratinocytes donor. (*P<0.05, ** P<0.01, ***P<0.005).  
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5.3 p53 IS DEGRADED VIA PROTEASOME PATHWAY 
IN 3 HPV E6/E7 HFKs  
As described in paragraph 1.21, the second key step towards the immortalization of the 
keratinocytes is the alteration of p53 functions, with a bearing on cell cycle arrest and 
apoptosis. 
Several studies have shown that different HPV types use distinct mechanisms to alter the 
function of the tumour suppressor p53 [12]. To date, HPV49 E6 is the only known  
HPV onco-protein that shares the same mechanism of HR HPV16 E6 in promoting p53 
degradation, via the interaction with E6AP and the proteasome pathway [138]. Therefore, 
the ability of the other 3 types to degrade p53 was tested.  
Immunoblotting analysis using a p53 specific antibody showed that p53 basal levels (-
Doxo) were lower in 3 E6/E7 expressing HFKs when compared to control HFKs (fig. 
18A). In the same condition, p53 was not detectable in HFKs expressing HPV16 E6/E7. 
In uninfected cells, p53 levels accumulate following cellular stress whereby p53 exerts its 
function as a cell cycle arrest effector, eventually promoting apoptosis. By contrast in 
HPV16 infected cells, p53 is not only degraded in normal conditions but also in the 
condition of cellular stress, allowing continuous proliferation [58]. To establish whether 
the 3 E6/E7 proteins could counteract p53 function in both stressed and non-stressed 
conditions, HFKs expressing E6/E7 were treated with doxorubicin (fig. 18A); 
doxorubicin is an intercalating agent that causes apoptosis of the cells via p53-dependent 
mechanisms. [145] 
As expected, high accumulation of p53 was detected after the treatment with doxorubicin 
in control HFKs, but no band was seen either before or after doxorubicin treatment in 
cells expressing E6/E7 from HR types 16 (fig. 18A). In 3 HPV E6/E7 HFKs, p53 
accumulation is attenuated compared to mock HFKs but still detectable by 
immunoblotting (fig. 18A). 
The accumulation and activation of p53 after cellular stress causes the up-regulation of a 
number of genes involved in the cell cycle and apoptosis, such as p53 up-regulated 
modulator of apoptosis (PUMA), as well as the primary mediator of p53-dependent cell 
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cycle arrest in response to DNA damage p21Waf1, a CDK inhibitor associated with the 
inhibition of Cdk2 [146, 147]. In keeping with previous work that showed p53 mediates 
cell cycle arrest and apoptosis, an increase in both PUMA and p21Waf1 mRNA levels was 
observed after doxorubicin treatment in mock HFKs (fig. 18B). On the contrary, despite 
the slight accumulation of p53 after doxo treatment (fig. 18A), no transcriptional 
activation of either p21Waf1 or PUMA was observed in HPV49 and HPV76 E6/E7 HFKs 
(fig. 18B). Instead, doxorubicin treatment of HPV75 E6/E7 keratinocytes resulted in a 
considerable increase of both p21Waf1 and PUMA mRNA levels (fig. 18B), suggesting that 
this  HPV type is less efficient than HPV49 and HPV76 in targeting p53. HPV75 cells 
appear to retain part of this function. As expected, p21Waf1 and PUMA mRNA levels were 
not increased after doxorubicin treatment in cells expressing E6/E7 from HPV16 (fig. 
18B). 
 
Figure 18: p53 is degraded in HFKs expressing E6/E7 from 3 types. (A) HFKs cells as 
indicated were treated for 8 hours with a DNA damaging agent doxorubicin (Doxo) used at the 
final concentration of 2 µg/ml or with DMSO as a control. Protein levels of p53 and β-actin 
were determined by immunoblotting using specific antibodies. (B) Total RNA extracted from 
cells treated as in figure 3A was retro-transcribed and used as a template for RT-Real-Time PCR 
analysis of PUMA and p21 gene expression, normalized to GAPDH. The result shown in the 
histogram is the mean of three independent experiments performed in one donor. (C) The 
indicated HFKs were treated for 4 hours with the proteasome inhibitor (MG132, final 
concentration 10µM), and protein levels of p53 and β-actin determined by immunoblotting using 
specific antibodies.  
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The low levels of p53 observed before and after doxorubicin treatment (fig. 18A) in 
HFKs expressing E6 and E7 from the 3 types indicate that p53 is targeted by 
degradation through the mediation of the viral onco-proteins, as previously demonstrated 
for HPV16 (see paragraph 1.2.1). Cells were therefore treated with proteasome inhibitor 
MG132. MG132 treatment caused an increase in p53 protein levels in HPV16 E6/E7 
HFKs, detectable with immunoblotting (fig. 18C). Similarly, there was the rescue of p53 
protein levels in HFKs expressing E6/E7 from HPV49, 75 and 76 (fig. 18C). On the 
contrary, no difference in p53 protein level was observed when MG132 treatment was 
applied on mock HFKs (fig. 18C). These results show that p53 is targeted for degradation 
by proteasome pathway also in cells expressing E6 and E7 from the 3 types. 
As described in paragraph 1.2.1, the ubiquitin ligase E6AP is involved in the HPV16 E6-
mediated degradation of p53. To examine its involvement in p53 degradation in 3 
E6/E7 HFKs, E6AP expression was silenced by small interfering RNA (siRNA) and p53 
protein levels were evaluated by immunoblotting (fig. 19A and 19B). In 3 E6/E7 HFKs 
the silencing of E6AP expression led to an increase of p53 protein levels (fig. 19A), 
similar to HPV16. The quantification of the immunoblots (fig. 19B) showed that the 
rescue of p53 was significantly higher in HPV16 E6/E7 HFKs when compared to 3 
HFKs, suggesting that a ubiquitin ligase different from E6AP might be also involved in 
the degradation of p53. 
In addition, maltose-binding protein (MBP) pull-down were performed with MBP-GFP 
or MBP-E6 fusion proteins and the interaction with p53 and E6AP proteins was analyzed 
with immunoblotting (fig. 19C and 19D). As shown in figure 19C, a light band 
corresponding to p53 was detected when cell lysate was incubated with HPV16 and 3 
E6-MBP fusion proteins but not when the cell lysate was incubated with the MBP-GFP 
fusion protein. Similarly, a band corresponding to E6AP was detected in all the E6-MBP 
fusion proteins, but a slight signal was detected using the control MBP-GFP fusion 
protein (fig. 19C). For this reason, quantification of the bands from different pull-downs 
was performed and the background signal from MBP-GFP fusion protein subtracted 
from the signal obtained with the E6-MBP fusion protein (fig. 19D). The pull-down 
experiments showed that E6 from 3 types form a complex with p53 and E6AP, even 
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though the binding detect via immunoblotting is lower when compared to the binding 
detected for HPV16 E6. 
 
Figure 19: p53 is degraded in HFKs expressing E6/E7 from 3 types with a mechanism 
similar to HR HPV16. (A) HPV16, 49, 75 and 76 E6/E7 transduced HFKs were transiently 
transfected with siRNA directed against E6AP (siRNA) or a scramble control (Scr). Levels of 
p53, E6AP and β-actin were determined by immunoblotting using specific antibodies. (B) Band 
intensities were quantified, normalized to β-actin levels, and then expressed relative to those 
treated with the scramble siRNA. Data are the means of three independent experiments 
performed in primary keratinocytes from two donors. (C) The indicated E6-MBP or MBP-GFP 
fusion proteins were incubated with 600 g HNC136 total protein extract. Levels of p53 and 
E6AP were determined by immunoblotting using specific antibodies. Fusion protein levels were 
determined with Ponceau staining. (D) Band intensities were quantified and normalized to the 
fusion protein levels and expressed as a percentage of the input. The histogram on the right panel 
shows the relative amounts of binding of p53 and E6AP to the different E6, compared to 
HPV16 E6, set as calibrator. The results are the mean of 5 independent experiments. (*P<0.05, 
** P<0.01, ***P<0.005).  
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5.4 3 TYPES 49, 75 AND 76 E6/E7 EFFICIENTLY UP-
REGULATE hTERT EXPRESSION 
A major step in the immortalization of HFKs by HPV16 E6 and E7 is the up-regulation 
of human telomerase (hTERT) transcription (see paragraph 1.2.1). Therefore, the mRNA 
levels of hTERT were assessed in control HFKs, HFKs carrying the empty plasmid and 
HFKs expressing E6/E7 from HPV16 and the 3 types. 
As shown in figure 20A, hTERT mRNA levels were significantly higher in HPV49, 75 
and 76 E6/E7 HFKs, when compared to both control HFKs and HFKs carrying the 
empty vector (pLXSNØ). On the contrary, the cells expressing E6 and E7 from HPV115 
show low levels of hTERT, comparable to HFKs and pLXSNØ HFKs (fig. 20A). As 
expected, hTERT transcription is highly up regulated in HPV16 E6/E7 expressing 
keratinocytes (fig. 20A). 
 
Figure 20: 3 E6/E7 HFKs with prolonged lifespan efficiently up-regulate hTERT 
expression. (A) total RNA extracted from cells at the same passage was retro-transcribed and 
used as a template for RT-Real-Time PCR analysis of hTERT gene expression, normalized to 
GAPDH. The result shown in the histogram is the mean of three independent experiments 
performed in two donors. (B) RT RT-PCR products of figure 20A (hTERT and GAPDH) were 
run on a 1.5% agarose gel. 
Given the very low level of hTERT mRNA in HFKs and pLXSNØ HFKs, this data set 
was then confirmed by loading the PCR product on an agarose gel (fig. 20B). The gel 
confirmed low levels of hTERT in HFKs and pLXSNØ HFKs. The presence of multiple 
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bands indicates the existence of different mRNA species derived from alternative splicing 
or non-specific amplification (fig. 20B). On the contrary, a very clear band of 
amplification was obtained for HFKs expressing E6 and E7 from HPV16 and 3 types. 
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5.5 HPV76 E6 TRANSFORMING PROPERTIES ARE 
AFFECTED BY MUTATIONS IN THE 
CORRESPONDING REGIONS OF HPV16 E6 
INVOLVED IN p53 AND E6AP BINDING  
Given the ability of 3 E6s to target p53 for degradation (fig. 18), the link between the 
interaction of E6 with p53 and the immortalization activity was evaluated. For this 
additional experiment, HPV76 has been selected as an example of the 3 immortalizing 
type.  
5.5.1 MUTANTS DESIGN 
Recent studies of the Zanier group in Strasbourg on the structure of E6-E6AP-p53 
complex have shown that four amino-acids of E6 are essential for the formation of the 
complex and for the subsequent degradation of p53 [88, 148]. The two aspartic acids in 
position 44 and 49 (D44, D49) are involved in the formation of a polar bridge with p53 
and mutations in these positions (D44R, D49R) result in the impaired formation of the 
complex and p53 degradation. The phenylalanine in position 47 is part of a hydrophobic 
core crucial for the interaction with p53 and its mutation (F47R) results in an impaired 
ability to degrade p53. Instead, the leucine in position 50 mediates the interaction between 
E6 and the LxxLL motif of E6AP and other cellular proteins and mutation in this 
position (L50E) results in a loss of E6AP binding and p53 degradation [88, 148]. 
Considering that E6 of 3 types 49, 75 and 76 have similar abilities to HPV16 in the 
degradation of p53, their sequences were aligned and compared to alpha HPV types (HR 
and LR) (fig. 21). The alignment showed that despite the E6s of 3 are shorter both at the 
N- and C-terminal, the overall sequence is conserved when compared to the alpha types 
(fig. 21). In particular, the region of interaction with p53 and E6AP described above is 
highly conserved, with the exception of the amino-acid of HPV115 corresponding to D49 
of HPV16 (fig. 21, close up). 
Based on these information, a set of four mutants was created via site direct mutagenesis 
on the sequence of E6 of HPV76. The four mutagenized amino-acids are E39, Y42, D44 
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and F45 and they correspond, respectively, to D44, F47, D49 and L50 of HPV16 E6 (fig. 
21).  
 
Figure 21: Alignment of the E6 protein sequences from different and  HPV types. 
Dark arrows indicate HPV16 E6 amino-acids directly involved in p53 binding, while light blue 
arrow indicates the amino-acid involved in binding the LxxLL motif of E6AP. Indicated in the 
figure the mutations of HPV16 E6 and their phenotype and the corresponding mutations 
designed for HPV76 E6. 
5.5.2 HPV76 E6 MUTANTS FAIL IN THE IMMORTALIZATION OF 
PRIMARY KERATINOCYTES 
To assess the ability of E6 mutants to immortalize HFKs, HFKs were transduced with 
HPV76 E6/E7 constructs carrying the wild type E7 and the wild type or the mutated 
E6s. As expected, and as previously shown, HFKs expressing WT E6/E7 showed an 
increased lifespan (fig. 22A) and the typical morphology of highly proliferative cells (fig. 
22B). On the contrary, the mutant F45E rapidly died after the end of the selection (fig. 
22A). HPV76 E6 E39R, Y42R and D44A were also unable to cooperate with wild type 
E7 in increasing the lifespan of the keratinocytes and subvert the senescence program 
even though, different to the F45E mutant, the cells remained in a senescent state for 
approximately 80-100 days before death (fig. 22A). The morphology of the cells reflected 
their inability to subvert the senescence, as shown in figure 22B.  
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Figure 22: HFKs expressing mutated E6 and wild type E7 do not become immortalized. 
(A) Growth curve of human primary keratinocytes expressing E6/E7 with wild type E6 or 
mutated E6, as indicated. Population doublings (PD) are shown on the y axis. (B) Morphology of 
HFKs transduced with the indicated recombinant retroviruses at PD2. The same magnification 
was used for all the microphotographs (20X).  
5.5.3 HPV76 E6 E38R, Y42R, F45E MUTANTS FAIL TO DEGRADE p53  
Given the short lifespan of the primary keratinocytes carrying the different mutant E6, 
naturally immortalized keratinocytes (NIKs) stably expressing WT E7 and WT or mutated 
E6 were generated. With this new experimental model, the ability of HPV76 E6 mutants 
to target p53 for degradation was analysed in comparison to the WT E6. 
The cells were treated with doxorubicin for 8 hours and then analysed via 
immunoblotting for p53 protein levels. As expected, p53 protein levels increased upon 
doxorubicin treatment while NIKs carrying HPV76 WT E6 and WT E7 showed low 
levels of p53 both in basal condition and after treatment (fig. 23A). These results also 
indicated that the doxorubicin challenge results obtained in HFKs are reproducible in 
NIKs and therefore that the new model is suitable for the study of the functionality of the 
E6 mutants. The immunoblotting shown in figure 11A shows that p53 levels were 
accumulated after doxorubicin treatment in NIKs expressing HPV76 E6 E39R, Y42R 
and F45E mutants when compared to their untreated counterparts (fig. 23A). 
Interestingly, among these mutants, only F45E shows increased level of p53 compared to 
control NIKs (pLXSNØ) in the untreated condition (fig. 23A). By contrast, p53 protein 
levels in the mutant D44A did not change with treatment (fig. 23A). The D44A mutant, 
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therefore, retained the ability of wild type E6 to prevent p53 accumulation induced by 
cellular stress. 
 
Figure 23: Mutation of HPV76 E6 in amino-acidic residues corresponding to p53 and 
E6AP binding sites in HPV16 E6, alter its biological activities. (A) NIKs transduced with 
E7 and with the indicated E6 or empty vector (pLXSNØ) as control, were treated with the DNA 
damaging agent doxorubicin (Doxo) used for 8 h (final concentration 10 mg/ml). Levels of p53 
and GAPDH were determined by immunoblotting using specific antibodies. (B) NIKs 
transduced as described in Fig 8A were treated with the protein synthesis inhibitor 
(Cycloheximide, final concentration 10 µg/ml) and collected at the indicated time points. Twenty 
micrograms of total protein extract from NIKs-pLXSNØ, WT and E39R E6 mutant were run on 
a separate immunoblotting than NIKs expressing Y42R, D44A and F44E E6 mutants (upper and 
lower panel respectively). Levels of p53 and GAPDH were determined by immunoblotting using 
specific antibodies. The histogram on the right side shows the quantification of the p53 signal, 
normalized to GAPDH levels and calibrated against the levels of p53 at 2 hours of treatment (set 
as 100%). Data are the means of three independent experiments. 
To further corroborate the data obtained on the efficiency of the different HPV76 E6 
mutants to target p53 for degradation, p53 half-life was determined. The cells were 
treated for 1, 2, 4 and 6 hours with cycloheximide (CHX), a chemical agent that blocks 
the de novo protein synthesis and therefore allows to calculate the stability of the protein of 
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interest. The protein extracts were analysed via immunoblotting using a p53 specific 
antibody. As shown in figure 23B, in pLXSNØ NIKs p53 levels decrease with time and 
after 6 hours approximately 60% of p53 protein is degraded (fig. 23B, right panel). 
Similarly to the pLXSNØ NIKs, p53 has a half-life of approximately 6 hours in NIKs 
expressing HPV76 E6 E39R, Y42R and F45E mutants (fig. 23B). Corresponding to 
results obtained with the doxorubicin challenge, HPV76 E6 WT and D44A mutant 
showed a decreased p53 half-life, with approximately only 20% of the protein remaining 
in the cells after 6 hours of cycloheximide treatment (fig. 23B).  
5.5.4 E39R E6 MUTANT FAIL TO UP-REGULATE hTERT 
EXPRESSION 
As described in paragraph 5.4, HPV76 E6 can up-regulate the transcription of hTERT, in 
a manner similar to HPV16. In HPV 16, an important role in the up-regulation of hTERT 
is played by E6 and some studies have shown that the interaction between E6 and E6AP 
might be involved [95, 96]. One of the mutations carried out in HPV76 E6 (F45E) is an 
amino-acid suspected to play a role in the binding with E6AP, possibly with a bearing on 
hTERT up-regulation.  
Therefore, the mRNA levels of hTERT were assessed in NIKs carrying the empty 
plasmid and NIKs expressing HPV76 wild type E7 and wild type or mutant E6. As 
shown in figure 24, NIKs carrying the wild type HPV76 E6/E7 have a higher level of 
hTERT mRNA when compared to control NIKs, a result that is mirrored in the primary 
keratinocytes (fig. 20A). Interestingly, the F45E E6 mutant induces high hTERT 
expression levels, similarly to the levels observed for the HPV76 E6 wild type (fig. 24). 
The levels of hTERT mRNA were also significantly higher in the Y42R and D44A 
mutants compared to mock NIKs (fig. 24). hTERT mRNA is considerably lower in the 
E39R mutant compared to the other E6 containing NIKS and resembles the NIKs cells 
expressing the empty vector (fig. 24). 
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Figure 24: HPV76 E6 mutants retain hTERT up-regulation ability with the exception of 
E39R mutant. Total RNA extracted from NIKs carrying the indicated constructs was retro-
transcribed and used as a template for were RT-Real-Time PCR analysis of hTERT gene 
expression, normalized to GAPDH. The result shown in the histogram is the mean of three 
independent experiments.  
The summary of the data obtained on the E6 mutants is shown in Table 13. The 
mutagenesis in all the amino-acids corresponding to the regions of HPV16 E6 involved in 
p53 and E6AP interactions results in an impaired ability to immortalize human primary 
keratinocytes. Interestingly, the D44A mutant retained the ability to degrade p53 and up-
regulate hTERT, indicating that a mutation of this particular amino-acid affects other E6 
properties that are essential for the extension of the life-span. Moreover, mutation of 
amino-acid 39 (E39R) led to an impairment in both the degradation of p53 and hTERT 
up-regulation, indicating that this amino-acid plays and important role in both pathways. 
On the contrary, the mutation of amino-acids 42 and 45 led only to the loss of p53 
degradation, confirming the role of these two amino-acids of HPV76 E6 dependent 
degradation of p53, as shown for the corresponding amino-acids in HPV16 E6. 
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Table 13: summary of the E6 wild type and E6 mutants properties. The immortalization 
ability has been tested in primary keratinocytes, while p53 degradation and hTERT up-regulation 
abilities have been tested in NIKs. The symbol  indicates a retained ability while the symbol  
indicates an abolished ability. The phenotype of HPV16 E6 corresponding mutants is briefly 
described.  
 
HFKs 
immortalization 
p53 
degradation 
hTERT 
up-
regulation 
In HPV16 
Wild type    
 
Mutant 1: 
E39R 
   
impair p53 ternary 
complex assembly and 
p53 degradation 
Mutant 2: 
Y42R 
   
defective for p53 
degradation 
Mutant 3: 
D44A 
   
impair p53 ternary 
complex assembly and 
p53 degradation 
Mutant 4: 
F45E 
   
decrease E6AP binding 
and p53 degradation 
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5.6 3 HPV AND HPV16 E6/E7 HFKs SHOW SOME 
SIMILARITIES IN THE ALTERATION OF 
CELLULAR GENE EXPRESSION 
To gain more insight into the biological properties of E6 and E7 from the 3 types, the 
impact of 3 HPV E6 and E7 proteins on cellular gene expression was determined. Total 
RNA from HFKs (donor 1) transduced with recombinant retroviruses expressing E6/E7 
of HPV49, 75, 76 and 115 was extracted and converted to cDNA, and subsequently to 
biotin-labelled single-stranded cRNA. The same procedure was carried out on HFKs 
carrying E6/E7 of HR type 16 and β2 type 38 as well as HFKs from two different donors 
transduced with an empty retrovirus. The samples were hybridized on HumanHT-12 
Expression BeadChips (Illumina) and the signals were read with the Illumina BeadArray 
Reader. Afterwards, the raw data were analyzed using BRB-ArrayTools software as 
described in material and methods by the “Genetic Cancer Susceptibility Group”, IARC 
(France). The two pLXSNØ HFKs were used as control and probes with a p-value of < 
0.001, with a minimum of 1.5-fold change compared to pLXSNØ HFKs and a False 
Discovery rate (FDR) of <0.01 were considered significantly differentially expressed. 
5.6.1 HIERARCHICAL CLUSTERING REVEAL HIGHER 
SIMILARITY BETWEEN 3 TYPES AND HPV16 E6/E7 
KERATINOCYTES 
First, the heat map of figure 25 was generated with the genes that are specifically de-
regulated by the expression of E6/E7 from the different 3 HPV types. This 
representation of the data is useful to have an overall overview of the de-regulated genes 
and it allows to visualize and compare the different conditions in a simple and effective 
method.  
As expected, the hierarchical clustering analysis revealed that among the 3 HPV types, 
the non-immortalizing HKFs expressing E6 and E7 from HPV115 have the most 
divergent profile from the mRNA profile of HPV16 (fig. 25). Interestingly, HPV38 
E6/E7 HKFs are more divergent from HPV16 than HPV115, despite the ability of 
HPV38 onco-proteins to immortalize primary keratinocytes (fig. 25). HFKs expressing 
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E6/E7 from HPV75 have a higher number of de-regulated genes compared to all other 
keratinocytes. This does not reflect in growth ability of these cells since E6/E7 of HPV75 
in donor 1 has a slower rate of growth when compared to HPV16, 49 and 76 expressing 
keratinocytes (fig. 25). 
 
Figure 25: 3 E6/E7 HFKs have an expression profile similar to HR type 16. Heat map of 
the significantly de-regulated genes in the HFKs expressing E6/E7 from the indicated HPVs. 
The colour represents the expression level of the gene: red represents the higher expression, 
while green represents lower expression compared to gene expression in empty vector HFKs. 
mRNA was extracted prior immortalization. 
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5.6.2 PATHWAY ANALYSIS REVEALS AN OVERALL DE-
REGULATION OF CELL CYCLE, p53 AND DNA REPLICATION 
PATHWAYS IN HFKs EXPRESSING E6/E7 FROM HPV49, 76 
AND HR HPV16 
Many studies have shown that viral onco-proteins have developed redundant mechanisms 
in deregulating cellular pathways. Thus, it is possible that viral proteins are able to 
deregulate the expression of genes encoding proteins involved in the same pathways. To 
evaluate this hypothesis an in silico pathway enrichment analysis was performed. 
 
Figure 26: Schematic representation of the in silico pathway analysis. The genes de-
regulated in E6/E7 from a specific HPV type (“gene set”) are compared with the KEGG 
database, using Enirchr algorithms. Enirchr software applies then statistical analysis and returns 
the results in the form of a histogram and a table with the enriched pathway and their statistical 
significance. 
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The enrichment analysis is a computational method for inferring knowledge on an input 
gene set, using annotated gene sets representing prior biological knowledge. For this 
experiment, the input gene set is represented by the genes de-regulated in E6/E7 
expressing keratinocytes while the annotated gene set is represented by the KEGG 
database, 2016 version (fig. 26). The enrichment analysis analyses whether there is an 
overlap between the input set and the annotated gene set, it then applies statistical analysis 
and calculates p-value, q-value, z-score and combined score in order to determine if the 
overlap is significant (fig. 26). The output obtained from the Enrichr software is a bar 
graph where the length of the bar represents the significance of that specific term. The 
brighter the color, the more significant that term is (fig. 26). For this experiment, the 
terms are ranked based on the combined score, from the more significant to the less 
significant. Moreover, a table with the statistical values can be obtained. 
Figure 27 shows the results of the pathway enrichment performed on the genes de-
regulated in HFKs expressing E6/E7 from HPV16, 38, 49, 75, 76 and 115 in comparison 
to mock HFKs. Of note, the size of the gene sets is different, with HPV75 E6/E7 HFKs 
having the biggest gene set (1085 de-regulated genes) and HPV76 E6/E7 HFKs having 
the smallest gene set (172 de-regulated genes) (fig. 27). Interestingly, the pathway analysis 
of HFKs expressing E6/E7 of HPV38 did not show a significant enrichment in any of 
the pathways in the KEGG database, with a combined score ranging from 1.27 to 1.76 
for the pathway showed in the bar graph of figure 27. 
The pathway analysis revealed that the genes de-regulated in the 3 HPV E6/E7 HFKs 
were enriched in cell cycle related genes, an enrichment shared also by HPV16 E6/E7 
HFKs but not by 2 type 38 E6/E7 HFKs (fig. 27 and table 14). Moreover, the analysis 
showed that only the 3 types E6/E7 that are able to prolong the HFKs lifespan have de-
regulated genes enriched in the p53 pathway and DNA repair, an enrichment obtained 
also for E6/E7 HPV16 HFKs but not for E6/E7 HPV38 HFKs (fig. 27 and table 14). 
Finally, only the immortalizing type 16, 49 and 76 share an enrichment in de-regulated 
genes involved in DNA replication (fig. 27 and table 14).  
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Figure 27: 3 E6/E7 HFKs share pathway enrichment with HPV16 E6/E7 HFKs. 
Pathway analysis (Enrichr) of the significantly de-regulated genes in cells expressing E6/E7 of 
the indicated HPVs. The length of the bar and the brightness of the colour represent the 
significance of the specific pathway (combined score range: HPV16 8.25-72.34; HPV38 1.27-
1.76; HPV49 6.88-72.91; HPV75 5.06-14.60; HPV76 2.57-6.99; HPV115 3.27-5.94). Gene set 
sizes are indicated by the number on top of each histogram. 
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Table 14: Summary of the enrichment pathway analysis. The HFKs expressing E6/E7 of all 
the β 3 types are enriched in the cell cycle pathway, while only the HFKs with prolonged lifespan 
(HPV49, 75 and 76) share enrichment in the p53/DNA repair pathway. Only the immortalizing β 
3 types share enrichment in the DNA replication pathway. The symbol  indicates that the 
pathway is found enriched in the HFKs expressing E6/E7 of that particular HPV type. The 
symbol  indicates that the genes de-regulated in HFKs expressing E6/E7 of that particular 
HPV type are not enriched in the indicated pathway.  
 Cell cycle 
(gene set size: 1706) 
DNA replication 
(gene set size: 296) 
p53 and DNA repair 
(gene set size: 594) 
HPV16    
HPV49    
HPV75    
HPV76    
HPV115    
HPV38    
5.6.3 3 E6/E7 EXPRESSING KERATINOCYTES SHARE MORE DE-
REGULATED GENES WITH HR HPV16 THAN WITH 2 HPV38 
The above experiments on E6/E7 properties from 3 types showed that E6 and E7 from 
HPV49, 75 and 76 shares some similarities with E6 and E7 of the HR type 16 
(paragraphs 5.2.2, 5.3 and 5.4). Moreover, the pathway analysis showed common 
enrichment of genes involved in cell cycle, DNA replication and DNA repair (paragraph 
5.6.2). Therefore, the similarity between the expression profiles of 3 HPV types and 
HPV16 E6/E7 HFKs was examined. For this, a comparative analysis between each of the 
3 HPV types, HPV16 and HPV38 expressing keratinocytes was performed. The Venn 
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diagram in figure 28A shows the type of analysis performed using HPV76 as an example 
and the results of all the comparative analysis are summarized in the histogram of figure 
28B. The genes de-regulated in HPV76 E6/E7 HFKs were compared to the genes de-
regulated in HPV16 E6/E7 HFKs and to the genes de-regulated in HPV38 E6/E7 
HFKs. The Venn diagram shows the number of genes similarly de-regulated in HPV16 
and HPV76, the genes similarly de-regulated in HPV38 and HPV76, the genes similarly 
de-regulated in HPV16, HPV38 and HPV76, and the genes exclusively de-regulated in 
HPV76 (fig. 28A). Of particular interest is the number of genes that HPV76 share 
exclusively with HPV16 or with HPV38. As shown by the percentages in the histogram 
of figure 28B, all the HFKs expressing E6/E7 from the 3 HPV types share more de-
regulated genes with HFKs expressing E6/E7 of the  type 16 than with HFKs 
expressing 2 HPV38 E6/E7. 
 
Figure 28: 3 HFKs shares more de-regulated genes with HPV16 than with HPV38 
HFKs. (A) Venn diagram of the genes de-regulated in the cells expressing E6/E7 from HPV16, 
HPV38 and HPV76. (B) Percentage of genes of the indicated 3 type that are also deregulated in 
HPV16 or HPV38. Common genes with opposite deregulation trends have been excluded from 
the analysis.  
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5.6.4 ARRAY VALIDATION 
As a final step, the gene expression data detected with Illumina platform was validated by 
RT RT-PCR. Both mRNA for the microarray and for RT RT PCR validation were 
extracted at the same cell passages, in the pre-immortalization status.  
Four genes were selected for the validation, based on their pattern of de-regulation in the 
different HPV types as well as their possible role in the immortalization process. 
The gene cdk2, which is involved in the regulation of the cell cycle, was found up-
regulated in cells expressing E6/E7 from HPV16, HPV49, HPV75 and HPV76 but not in 
HPV115 when compared to HFKs. The RT RT-PCR analysis confirmed the data 
obtained from the array (fig. 16B). 
SERPINE1 encodes for the plasminogen activator inhibitor 1 (PAI1), a serine protease 
inhibitor that functions as the principal inhibitor of tissue plasminogen activator (tPA) 
and urokinase (uPA). Interestingly, elevated levels of PAI1 in oral squamous carcinoma 
(OSC) are a prognostic marker of poor outcome while a low level of PAI1 is detected in 
HPV-positive OSC [149]. Confirming the data of the array, down-regulation of 
SERPINE1 was found in HFKs expressing E6/E7 from HPV16, 49 and 76 while up-
regulation was found in HFKs expressing E6/E7 from HPV75 and 115 when compared 
to mock HFKs (fig. 29A). 
GADD45a is a gene that is highly transcribed following cellular stress-dependent growth 
arrest or treatment with the DNA-damaging agent, and its transcription is mediated by 
both p53-dependent and p53-independent mechanisms. Interestingly, GADD45a is up-
regulated in the HFKs expressing E6/E7 of HPV75 and HPV115 but not in the other 3 
HPV types or in HPV16 E6/E7 expressing keratinocytes (fig. 29B).  
The last gene tested for the array validation is MT1X, a Metallothionein whose function is 
still not fully understood. However, a recent study showed that a significant loss of MT1X 
expression is observed in Oral Squamous Cell Carcinoma [150]. The RT RT-PCR on this 
gene showed a significant loss of MT1X in in HFKs expressing E6/E7 from HPV16, 49 
and 76 but not in HPV75 and HPV115 E6/E7 expressing keratinocytes (fig. 29C).  
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Figure 29: total RNA extracted from the indicated E6/E7 expressing HFKs (donor 1) was retro-
transcribed and used as a template for were RT-Real-Time PCR analysis of SERPINE1, 
GADD45a and MT1X gene expression, normalized to GAPDH. The result shown in the 
histogram is the mean of three independent experiments.  
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5.7 METABOLISM AND TRANSFORMATION 
In cancer development, the rewiring of the cellular metabolism is a key process for the 
cancer cells to support the new biosynthetic needs, in particular, cellular metabolism must 
adapt to support the increased cell proliferation seen in cancer cells. The first evidence 
showed that different to normal non-cancerous cells, the metabolism of cancer cells relies 
mostly on glycolysis, even in the presence of sufficient oxygen [151]. More recent studies 
have shown that the glucose metabolism is not the only altered metabolic pathway, but 
also nucleotides and protein synthesis are altered to support the transformation of the 
cells [152]. 
Additionally, the presence of HPV16 onco-proteins favors metabolic changes that might 
be important for the cellular transformation. As an example, a study showed that the 
expression of E7 from HPV16 causes a significant increase in the glycolytic rate and a 
significant increase in the conversion of glucose to lactate [153]. This study showed that 
E7 is also able to physically interact with M2-pyruvate kinase, an enzyme that plays a 
crucial role in metabolism reprogramming and cell cycle progression [154], stabilizing the 
dimeric form in presence of metabolites that favor the tetrameric form [153, 75].  
The alteration of metabolism in HPKs expressing E6/E7 from different HPV type can be 
detected not only inside the cells but also in the alteration of the intake or secretion of 
metabolites. Of particular interest could be the secretion of new metabolites or an 
increase in a metabolite secretion as a marker of infection. Therefore, in collaboration 
with the Nutrition and Metabolism - Biomarkers Group of IARC, metabolites produced 
by the HFKs expressing E6/E7 from the 3 HPV types and from HPV16 were analyzed 
by liquid chromatography coupled with the mass spectrometry (LC/MS). The LC/MS 
and the subsequent processing of the data were performed by William Cheung.  
To better understand the results obtained on the metabolites produced by the HFKs 
expressing E6 and E7, a brief overview of the experimental model is given below and it’s 
schematically represented in figure 30. 
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Figure 30: Schematic representation of the metabolites analysis experimental design. 
Human primary keratinocytes were stably transduced with E6 and E7 of 3 HPV types or E6 
and E7 from HPV16 and kept in culture on a feeder layer. At passage 10 the supernatant was 
collected, divided into 5 aliquots and the cells counted; the supernatant was collected, and the 
cells counted at PD3 for HPV115 E6/E7 expressing keratinocytes and at PD4 for HFKs. The 
supernatant was also collected from 3 cultures of a feeder layer. The supernatants were diluted in 
order to normalize against the number of cells and analyzed via liquid chromatography coupled 
with mass spectrometry. Three aliquots of FAD media were also analyzed via LC coupled MS. 
After the stable expression of E6 and E7 from the different HPV types, the cells have 
been kept in culture and at PD10 the supernatants were collected, and the cells were 
counted. For the HFKs expressing E6/E7 of HPV115, the supernatant was collected at 
PD3, given their short lifespan. Also for the donor HFKs, the supernatant was collected 
at earlier PD (PD4), a passage in which the cells are still actively proliferating and do not 
show any sign of senescence. As a control, NIH/3T3 fibroblasts inactivated with 
mitomycin C (only feeders) were cultured with FAD media and after 2 days the 
supernatant was collected and the cells were counted. Afterwards, the supernatant 
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samples were cell-count normalized by dilution in the FAD media and analyzed with 
liquid chromatography (LC) in tandem with mass spectrometry (MS). Additionally, a 
sample of FAD media was analyzed via LC coupled with MS (fig. 30). 
The MS features obtained from the LC/MS were processed as schematically represented 
in figure 31: the features found in the FAD media or in the feeder cells were not retained 
for further analysis as they are not the product of the HFKs metabolism. All the features 
that were not present in all the 5 replicates of each HPV type were discarded as 
considered unreliable data. Ultimately, only MS features that could be matched to 
metabolites in either the Human Metabolome Database or the METLIN database based 
on their accurate mass were retained. All the MS features that were retained were tested 
with Kruskal-Wallis ANOVA and manually checked and corrected for integration error 
(fig. 31).  
 
Figure 31: Schematic representation of the raw data preprocessing and filtration. The MS 
features obtained from the LC/MS were filtered and features present also in FAD media and in 
the feeder at were discarded. A quality control filter was applied, and all the features not present 
in the 5 replicates of the same sample were discarded. The remaining features were tested with 
Kruskal-Wallis ANOVA and manually checked.  
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The ion abundance of each feature in E6/E7 HFKs was compared to the corresponding 
ion abundance in primary keratinocytes and only the features with a significant difference 
were used for the heat map and the hierarchical clustering map generation.  
After processing, 54 significant MS features were found in the positive mode and 16 
features were found in the negative mode. Heat map and hierarchical cluster analysis 
(HCA) were generated using the online graphic user interface platform “Metaboanalyst” 
on the retained features and the results are shown in figures 32 and 33, respectively for 
the positive and negative mode. In the heat map, the red represents metabolites that are 
more concentrated in the E6/E7 keratinocytes than in the mock HFKs, therefore, they 
are metabolites that are produced by the E6/E7 HFKs. By contrast, the blue represents 
metabolites that are less concentrated in the E6/E7 keratinocytes than in the mock 
HFKs, therefore, they are metabolites that are not produced or produced less by the 
E6/E7 HFKs.  
The heat map on the positive mode MS feature (fig. 32, left panel) shows that HPV76 and 
HPV49 E6/E7 expressing HFKs have a very similar pattern of metabolite de-regulation, 
correlating with the similarities observed in the growth abilities and in the interference 
with the major cellular pathways. HPV16 and HPV115 E6/E7 expressing HFKs have 
very different metabolites de-regulation patterns, results expected given the opposite 
ability of E6 and E7 of these types to immortalize the keratinocytes (fig. 32, left panel). 
The hierarchical cluster analysis (fig. 32, right panel) revealed that the 5 replicates of each 
HPV type in the positive mode cluster together, indicating that the results obtained are 
reliable. Moreover, as shown also in the heat map, HPV115 (in red) is clustering alone 
and it is the more distant from both HPV16 and the other 3 E6/E7 expressing HFKs 
(fig. 32, right panel). As observed in the heat map, the HCA showed that HPV49 and 
HPV76 E6/E7 expressing HFKs cluster together while HPV75 E6/E7 expressing HFKs 
cluster with HFKs expressing E6/E7 from HPV16 (fig. 32 right panel). 
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Figure 32: Immortalizing 3 E6/E7 HFKs cluster together with HPV16 E6/E7 HFKs in 
positive mode metabolism LC/MS analysis. The heat map of the positive mode was 
generated using the 54 retained MS features obtained after the processing. In blue the molecules 
that are less present in the samples than in the HFKs and in red the molecules more present in 
the samples than in the HFKs (left panel). The 54 retained MS features were used to generate a 
hierarchical clustering dendrogram, using Euclidean distance and ward clustering algorithm (right 
panel). The length of the arms is a measure of similarity between the sample. 
The heat map on the negative mode MS feature (fig. 33, left panel) shows that HPV76 
and HPV49 E6/E7 expressing HFKs have a very similar pattern of metabolite de-
regulation, similar to what was shown on the positive mode. For the negative mode, 
HPV16 and HPV115 E6/E7 expressing HFKs have almost opposite metabolite de-
regulation (fig. 33, left panel). The hierarchical cluster analysis (fig. 33, right panel) 
revealed that the 5 replicates of HFKs expressing E6 and E7 from HPV49 and 76 do not 
perfectly cluster within the types, indicating a less accurate analysis compared to the 
positive mode. Moreover, as shown also in the heat map, HPV75 and HPV16 E6/E7 
expressing HFKs cluster together and the remaining 3 E6/E7 expressing HFKs cluster 
together (fig. 33, right panel). The negative mode pole results are not in concordance with 
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the positive mode results and they are overall less accurate when compared to the positive 
mode. It is important to note that the number of feature of negative mode before the 
processing is significantly lower compared to the positive mode. 
 
Figure 33: HPV16 and HPV75 E6/E7 HFKs cluster together in negative mode 
metabolism LC/MS analysis. The heat map of the positive mode was generated using the 16 
retained MS features obtained after the processing. In blue the molecules that are less present in 
the samples than in the HFKs and in red the molecules more present in the samples than in the 
HFKs (left panel). The 16 retained MS features were used to generate a hierarchical clustering 
dendrogram, using Euclidean distance and ward clustering algorithm (right panel). The length of 
the arms is a measure of similarity  
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6 DISCUSSION AND CONCLUSIONS 
The first beta HPV types (HPV5 and 8) were isolated from the skin of patients suffering 
from the genetic disease epidermodysplasia verruciformis (EV).  HPV genomes have been 
detected in 90% of the squamous cell carcinoma in patients with EV [103, 104]. 
Moreover,  HPV genomes have been detected in skin warts and in SCC of organ 
transplant recipient patients, supporting the hypothesis that  HPVs are the etiologic 
agent of NMSC in immunosuppressed individuals [112, 113, 114]. However,  HPV 
genomes are also detected in the skin of healthy immune-competent individuals [115, 
116]. As a consequence, all the beta HPV types belonging to the 5 species (beta-1-5) are 
classified, by assumption, as cutaneous types.  
Epidemiological studies on the association between  HPVs and cutaneous SCC have 
shown that 1 and 2 genomes are often found on the skin of immune-competent 
individuals [155, 156, 157]. In particular, the findings of a recent meta-analysis suggested 
an association between the 1 and 2 HPV types 5, 8, 15, 17, 20, 24, 36, and 38 and 
development of SCC [155]. Epidemiological serological studies have also suggested an 
association between SCC and  HPV types, in particular with the 1 HPVs [156]. On the 
contrary, in all the studies mentioned above, 3 HPV types were rarely found on the skin 
of healthy individuals and they were never associated with an increased risk of SCC 
development [157].  
Interestingly, recent epidemiological studies have shown that 3 HPV types are found, 
with different prevalence, in mucosal epithelia [137, 135]. Hampras et al. showed that the 
3 HPV types are differently distributed at different anatomical sites. HPV49 appears to 
be more abundant in the mucosal tissues (anal and oral mucosa) than in the keratinized 
tissues (genital and forearm skin, eyebrow hairs). Instead, HPV76 is equally distributed in 
eyebrow hair and anal mucosa but is present with low prevalence in the oral mucosa. 
HPV75 has been detected in the anal mucosa, with low prevalence in eyebrow hair and 
forearm skin [135]. Another recent epidemiological study showed that HPV115 is rarely 
found in the mucosal anatomical sites (genital, anal canal and oral cavity), an expected 
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result given the non-transforming abilities of E6 and E7 of this type [158]. In the same 
study, HPV76 is the 3 type with the highest prevalence in genital and anal canal tissue, 
13.1% and 6% respectively, followed by HPV49 with 7.9% prevalence in genital tissue 
and 3.5% in the anal canal. HPV75, paralleling the lower transforming abilities of its 
E6/E7, is found in the genital tissue and in the anal canal with only 3.3% and 1.1% 
prevalence [158].  
The data contained in this thesis demonstrates that the 3 types are a sub-group of HPVs 
that share some biological similarities with both 2 HPV types (e.g. HPV38) and HR  
HPV types (e.g.HPV16). The mechanism of interaction of 3 E6 and E7 with the pRb 
pathway is similar to what is known for the 2 type 38 [120]. The expression of  HPV 
types E6 and E7 in in vitro models leads to an accumulation of the phosphorylated form 
of pRb, which loses its ability to bind E2F, while mucosal HR HPV types induce the 
degradation of hypo-phosphorylated pRb with the consequent release of E2F 
transcription factors [65]. Contrarily, 3 HPV E6 and E7 can induce an accumulation of 
p16INK4a in a manner similar to E7 derived from the HR  types [81]. Moreover, 3 types 
shares with HR  type 16 the ability to degrade p53 via the proteasome pathway, 
mediated by the interaction with the ubiquitin ligase E6AP, while 2 HPV38 E7 
promotes the accumulation of p53 and p73 antagonist ΔNp73 [86, 85, 84, 58, 121]. The 
expression profile analysis showed that 3 immortalizing types share with HR HPV16 an 
enrichment of de-regulated genes involved in p53, DNA repair pathway and DNA 
replication. Interestingly, both  type 16 and 2 type 38 induce the up-regulation of 
hTERT expression, a property also shared by 3 immortalizing types.  
The phylogenetic classification of papillomaviruses is based on the gene sequence of the 
major capsid protein L1, and the DNA sequence of the L1 ORF must differ by more than 
10% from the closest known PV type to be considered a new type [1]. To date, only four 
3 HPVs have been isolated, but the existence of additional types cannot be ruled out. It 
is likely that with the introduction of next-generation sequencing technology new PV 
types will be found. The presence of the known 3 HPVs in mucosal tissue and their 
biological properties suggest that the research of new 3 should be carried out in an 
Discussion and conclusions  
116 
 
anatomical region other than skin. Moreover, the phylogenetic assembly does not 
necessary reflect the biological properties or the tissue tropism of the viruses. 
Corroborating this statement, the alpha genus includes mucosal as well as cutaneous 
types. Among the mucosal types, there are low-risk and high-risk HPV types that are 
associated, respectively, with benign and malignant genital lesions [159]. Hence, it is 
plausible to hypothesize that not all the  HPVs share similar tissue tropism and 
biological properties. 
The biological similarities between HPV49 and HPV16 onco-proteins are further 
corroborated by in vivo studies on mouse models. Massimo Tommasino’s group have 
developed two different transgenic mice (Tg) models that express 2 HPV38 or 3 
HPV49 E6 and E7 proteins in epithelial cells under the control of the keratin 14 
promoter. These animal models have highlighted the ability of the  HPV types to 
synergize with different environmental risk factors in promoting cancer development. 
Viarisio et al. showed that Tg mice expressing E6/E7 of HPV16 and HPV49 in the basal 
layer of the epithelia are highly susceptible to the development of upper digestive tract 
cancer upon treatment with the tobacco-equivalent chemical 4-nitroquinoline 1-oxide 
(4NQO) [139]. Whole exome sequencing of DNA extracted form upper-digestive tract 
cancers revealed that 4NQO treatment promoted accumulation of DNA mutation 
signature of tobacco use (unpublished data). By contrast, wild type mice and Tg mice 
expressing E6/E7 from HPV38 treated with 4NQO developed a significantly lower 
number of lesions, mostly histologically benign in origin [139]. Vice versa, 2 HPV38 E6 
and E7 Tg mice are highly susceptible to UV-driven skin carcinogenesis [131, 130]. 
Exposure to chronic UV irradiation resulted in the development of AK-like lesions and 
subsequently of SCC [130]. Whole exome sequencing showed that chronic UV irradiation 
of 2 HPV38 E6/E7 transgenic mice resulted in the accumulation of a large number of 
UV-induced DNA mutations, which resembles the mutation pattern detected in human 
NMSC [131]. Using the same model of UV-exposure, the wild type and the Tg mice 
expressing E6/E7 HPV49 did not develop skin cancer and did not accumulate UV-
induced mutations [139, 130].  
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It is not yet clear whether 3 HPV types are involved in specific human pathological 
conditions, such as cancer. To date, there are no available studies on the presence of 3 
HPVs in tumour tissue. A well-recognized hypothesis is that 1 and 2 HPVs act with a 
“hit and run” mechanism, favoring the initial stage of tumour development and the 
accumulation of UV-induced mutations. Supporting this hypothesis, a recent in vivo study 
on Tg expressing 2 HPV38 E6/E7 in the basal layer of the epithelia showed that the 
knock down of E6/E7 expression after the development of the cancerous lesions do not 
cause a regression of the tumour [131]. Moreover, 2 HPV genomes are usually found in 
high copy number/cell (>50 copies/cell) in the pre-cancerous AK tissue while the 
genomes are almost completely lost with the development of SCC (less than 1 copy/cell), 
indicating a loss of HPV genome during the cancer development [118].  
It is plausible to hypothesize that also the 3 HPV types act with a “hit and run” 
mechanism, with E6 and E7 favoring the accumulation of mutations caused by additional 
environmental factors. 3 HPVs might play an important role in the early stage of the 
tumour development and in the establishment of a transformed phenotype of the cells.  
To better understand the role of 3 HPVs in the development of cancer, it would be 
interesting to characterize the changes in the methylome induced by the expression of 3 
E6/E7 and compare it with the signature of fully characterized human cancers. Changes 
in the DNA methylation are an irreversible epigenetic signature driven by environmental 
factors. Several studies have reported that HPVs are able to interfere with the DNA 
methylation machinery, creating methylome signatures [160]. Supporting this notion is 
evidence that the progression from normal tissue to HPV-driven cervical cancer is 
associated with a progressive cellular genome hypomethylation [161]. However, certain 
genomic DNA regions become hypermethylated, causing the silencing of the tumour 
suppressor genes (reviewed in [162]).  
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6.1 FUTURE PROSPECTIVES 
The data presented in this thesis characterized some of the 3 E6/E7 functions, however, 
some questions require further clarification. 
The data presented here show that E6 is able to interact with E6AP, however, it has been 
previously shown that HPV E6 proteins preferentially interact with MAML1 over E6AP, 
with the exception of the  HPV types [123]. Moreover, White et al. showed that HPV76 
is able to degrade p53 but preferentially binds MAML1 over E6AP [122]. Both MAML1 
and E6AP contain the same LXXLL motif that is recognized by the different E6 proteins 
and, given the similarities between 3 and the  HPV types, it is plausible to hypothesize 
that 3 E6s are able to physically interact with both MAML1 and E6AP. The analysis of 
mutation on the HPV76 E6 region responsible for the interaction with p53 and E6AP 
showed that D44A mutant retain both the ability to degrade p53 and up-regulate hTERT, 
however it is unable to collaborate with E7 in the immortalization assay. A possible 
explanation could be that this particular mutant is still able to interact with p53 and E6AP 
but the interaction with MAML1 is impaired, causing the inability to immortalize the 
HFKs. Further molecular analysis is required to understand the interaction of 3 E6s with 
both MAML1 and E6AP.  
Another interesting question is the biological significance of p16INK4a overexpression. In 
fact, it has been previously shown that in HPV16 E6/E7 expressing HFKs, p16INK4a 
favors proliferation and survival through more than one molecular mechanism 
=[82]=[82]. It remains unclear if 3 E6/E7 HFKs are also “addicted” to the up-
regulation of p16INK4a and how this protein, which is normally classified as a tumour 
suppressor, plays a role in the transformation process of 3 HFKs.  
Finally, the association between 3 HPVs and human diseases could be facilitated by the 
identification of markers of infection. For this purpose, the analysis of the metabolome 
was performed. The initial data highlighted differences in metabolite secretion between 
the immortalizing and non-immortalizing types. Additional studies are required to 
characterize these differences with the view to find potential disease or pre-malignant 
lesion biomarkers to aid disease identification. 
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ACRONYMS AND ABBREVIATIONS 
⁰ C: Degree Celsius 
4NQO: 4-nitroquinoline 1-oxide 
AK: actinic keratosis 
Amp: Ampicillin 
APS: Ammonium persulfate  
bp: base pairs 
CDK: cyclin dependent kinase 
Chl: Chloramphenicol 
CIN: Cervical intraepithelial neoplasia 
DMEM: Dulbecco´s modified Eagles 
medium  
DMSO: Dimethyl sulfoxide  
Ds: Double stranded  
E.coli: Escherichia coli  
E6: Human papillomavirus early protein 6  
E6AP: E6 Associated protein 
E7: Human papillomavirus early protein 7  
EDTA: Ethylen-di-amino-tetra-acetate  
EV: epidermodysplasia verruciformis 
Fw: primer forward 
H: Hours  
HAT: histone acetyl transferase 
HFK: human foreskin keratinocyte 
HPV: Human Papillomavirus 
HR: High risk 
hTERT: human telomerase 
K14: keratin 14 
Kan: Kanamycin 
kb: Kilo base pair  
kDa: kilo Dalton  
l: Liter  
L1: Human papillomavirus major capsid 
protein  
L2: Human papillomavirus minor capsid 
protein  
LB: Luria Broth  
LR: low risk 
M: Molar  
mA: milli Ampère  
MAML1: mastermind-like 1 
MBP: maltose binding protein 
min: minutes  
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ml: Milliliter  
mM: Millimolar  
mRNA: Messenger RNA  
MS: Mass-spectrometry  
nM: Nanomolar  
NMSC: Non melanoma skin cancer 
ORF: open reading frame 
Ori: Origin of replication  
OTR: organ transplant recipients 
PBS: Phosphate buffered saline  
PBS-Tween: Phosphate buffered saline-
tween  
PCR: Polymerase chain reaction  
PDGF: Plated derived growth factor  
PV: Papillomaviruses 
Rb: Retinoblastoma protein  
Rev: primer reverse 
 
 
 
 
 
RNA: Ribonucleic acid  
rpm: Revolutions per minute  
RT: Room temperature  
SCC: Squamous cell carcinoma 
SDS: Sodium dodecyl sulfate  
siRNA: Short interference RNA  
TEMED: N,N,N´,N´-tetra-
methylethylendiamin  
Tg: Transgenic 
URR: Upstream regulatory region 
UV: ultra-violet 
wt: Wild type 
g: Microgram  
l: Microliter  
M: Micromolar 
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 AMINO ACIDS  
One letter symbol Amino-acid 
A Alanine 
C Cysteine 
D Aspartate 
E Glutamate 
F Phenylalanine 
G Glycine 
H Histidine 
I Isoleucine 
K Lysine 
L Leucine 
M Methionine 
N Asparagine 
P Proline 
Q Glutamine 
R Arginine 
S Serine 
T Threonine 
V Valine 
W Tryptophan 
Y Tyrosine 
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